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 ABSTRACT OF DISSERTATION 
SLEEP ALTERATIONS IN MOUSE GENETIC MODELS OF HUMAN DISEASE 
 
Sleep is a process essential for the well-being of an animal and in humans as much 
as one-third of our life is spent in sleep. Yet, the biological need for sleep still remains a 
conundrum. Our knowledge of the genes influencing sleep and the mechanisms regulating 
the process can be advanced with the utilization of genetic and genomic approaches which, 
in turn, may inform us about the functions of sleep as well. With this goal, I have 
investigated and examined sleep-wake phenotypes for a variety of transgenic and knock 
out animals.  
 
For the first part of my research (Chapter 3), I examined mouse models of 
Alzheimer’s disease, and a combined model of Alzheimer’s disease (AD) and Diabetes. 
Sleep disturbances in case of AD are evident long before the onset of cognitive decline. I 
investigated sleep-wake alterations in 5XFAD, a double transgenic mouse model of AD 
which displays an early onset of AD pathology and cognitive impairments. We found that 
these mice have shorter bout lengths under baseline conditions. This was true for both 
sexes, however, the effect was more prominent in females. Additionally, females also had 
a shorter duration of sleep compared to control animals. These overall bout length 
reductions are indicative of increased sleep fragmentation similar to the ones seen in human 
AD patients.  
 
Inadequate sleep is associated with increased risk for metabolic disorders such as 
diabetes besides neurodegenerative diseases such as AD. There is also growing evidence 
that type 2 diabetes mellitus (T2DM) poses an increased risk of AD. To understand how 
the two conditions interact, we studied a combined mouse model of AD and diabetes 
(db/AD) which was generated by crossing of db/db (diabetic obese mice) and APP-PS1 
(knock-in AD mouse model). The resulting mice showed profound cerebrovascular as well 
as AD pathology. Both females and males, diabetic AD animals had longer sleep duration 
compared to non-diabetic AD animals. They also exhibited attenuated sleep-wake rhythms. 
Females were found to have shorter sleep bouts than males. In addition, significant two 
way interactions were found for the age and db/AD genotype. Our findings suggest that db 
genotype and not cerebrovascular pathologies affect sleep in our mouse model. For the last 
part of my research, we analyzed over 300 single gene knock out mouse lines generated on 
a C57BL6/NJ background, monitored at The Jackson Laboratory. With this unbiased 
approach where the knockouts were chosen at random, we identified 55 novel genes 
affecting various sleep traits, utilizing a variety of statistical approaches. Sex differences 
were found for a number of knockouts as well as controls. Control females were found to 
have shorter bout lengths and less sleep duration compared to male littermates.  
 
Keywords: amyloid beta, sleep fragmentation, diabetes, phenotyping, piezoelectric 
system, knockout mice 
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Chapter 1 Introduction 
Sleep is a complex behavior regulated by circadian and homeostatic processes. The 
circadian process gives time context to most physiological processes including sleep by 
entraining internal rhythms to the daily photoperiod. On the other hand, the homeostatic 
process works like an hour glass and tracks sleep need. In the absence of sleep, sleep need 
accumulates and in the presence of sleep, it dissipates (Borbely 1982, Flores, Flores et al. 
2007, Franken, Thomason et al. 2007, Maret, Dorsaz et al. 2007, O'Hara, Ding et al. 2007, 
Wisor, Striz et al. 2007, Andretic, Franken et al. 2008). Though the two processes develop 
independently of each other, their interaction determines the sleep and wake parameters of 
timing, duration, and quality (O'Hara, Jiang et al. 2017). 
Many genes related to the circadian system have already been well characterized, 
however much remains unknown about the homeostatic process of sleep and its general 
functions (Flores, Flores et al. 2007, Franken, Thomason et al. 2007, Maret, Dorsaz et al. 
2007, O'Hara, Ding et al. 2007, Wisor, Striz et al. 2007). Early evidence of genetic 
regulation of sleep comes from twin studies which showed that monozygotic twins have 
more similarity in their brain architecture and higher concordance for EEG spectrum traits 
than dizygotic twins (Stassen, Lykken et al. 1988, Ambrosius, Lietzenmaier et al. 2008, De 
Gennaro, Marzano et al. 2008). Further, it was found that for many EEG traits more than 
80% of the phenotypic variance could be attributed to genetic factors (i.e. 80% heritability).  
Sleep disturbances and disorders are common in today’s society. An estimated 30 
to 40% of adults show signs of insomnia and nearly 5 to 15% have problems with excessive 
daytime sleepiness (Bamne, Mansour et al. 2010). Inadequate sleep results in cognitive 
deficits which include increased reaction time, and impaired reasoning and decision 
making. Such deficits are a serious cause of concern in operational set-ups where they 
elevate risks of accidents and chances of making fatal errors (Killgore, Rupp et al. 2008), 
including medical errors (Ker, Edwards et al. 2010, Mongrain, Hernandez et al. 2010, 
Rillich, Schildberger et al. 2011, Bertram and Rook 2012, Callander, Bolton et al. 2012, 
Reichert and Gerhardt 2013). Apart from day to day risk, there is growing evidence that 
sleep disturbances are also a risk factor for disorders such as neurodegenerative diseases 
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including Alzheimer’s and Parkinson’s disease, hypertension, obesity, depression, 
diabetes, heart attack and the metabolic syndrome (Bamne, Mansour et al. 2010, Bertram, 
Rook et al. 2011, Pack and Pien 2011). Efforts aimed at improving sleep quality and 
treatment of sleep disorders are limited by our rudimentary knowledge of sleep functions 
and the mechanisms that regulate these functions. Identification of the genetic influences 
and elucidation of underlying mechanisms would therefore be critical in developing novel 
drugs targeting these regulators or other molecules that influence sleep.  
One approach to broaden our understanding of sleep regulation is by use of genetic 
resources such as transgenic and mutant animals. Given that sleep studies in humans tend 
to be difficult and expensive, it calls for generating animal models for human diseases that 
recapitulates sleep alterations seen in human conditions. As mentioned earlier, sleep 
disturbances are often seen in many neurodegenerative diseases including AD. AD is the 
most common form of dementia and associated sleep perturbations such as increased 
daytime sleepiness, fragmented sleep is the single biggest cause for institutionalization of 
patients, as middle of the night wanderings put both AD sufferer and caregivers at increased 
risk (Pollak and Perlick 1991, Vitiello, Poceta et al. 1991).  
AD pathology begins at least 10-15 years before clinical onset of the disease (Kang, 
Lim et al. 2009, Potvin, Lorrain et al. 2012, Sterniczuk, Theou et al. 2013, Hahn, Wang et 
al. 2014). Drug regiments successful in animal models have not offered any symptomatic 
relief or delay in progression in the case of human clinical trials, which calls for a different 
approach towards the treatment and mechanistic dissection of AD. It is proposed that 
therapeutic interventions may prove more successful if targeted at preclinical stages; before 
pathological changes become irreversible or too extensive to repair. This calls for potential 
biomarkers or behaviors that could identify the preclinical pathologies and provide 
alternative drug targets. Improving sleep and wake quality is an exciting potential target 
not only to improve life quality, but may even directly impact disease progression. Sleep 
alterations precede cognitive impairments and begin in parallel with accumulation of Aβ 
plaques (Anafi, Pellegrino et al. 2013, Aoyama and Nakaki 2013, Dyakonova and 
Krushinsky 2013, Fitzsimmons and Bertram 2013, Ju, McLeland et al. 2013, Malkki 2013, 
Möller-Levet, Archer et al. 2013, Simon, Greenaway et al. 2013, Spira, Gamaldo et al. 
2013, Stevenson and Schildberger 2013, Vagelatos and Eslick 2013, Yoo, Mohawk et al. 
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2013, Ju, Lucey et al. 2014). Also, sleep is shown to have a role in clearance of toxic 
metabolites like Aβ resulting from neuronal activity (Xie, Kang et al. 2013). Recent 
developments suggest that a positive feedback loop might exist between sleep perturbations 
and AD pathology, such that each factor might amplify the other, driving the progression 
of disease. Therefore, for my first project, detailed in chapter two, I evaluated sleep-wake 
alterations in 5XFAD, a mouse model for AD (Oakley, Cole et al. 2006).  
Insufficient sleep also has been linked to elevated risk of metabolic disorders such 
as obesity and diabetes (Knutson, Spiegel et al. 2007). Previous studies have shown that 
the leptin-resistant diabetic animals have diminished sleep wake rhythms (Laposky, 
Bradley et al. 2008). Also, there is increasing evidence that diabetes and obesity present a 
risk for AD development (Ott, Stolk et al. 1999, Kroner 2009). To study how the interaction 
of the two disorders effect sleep, we took advantage of the combined model of AD and 
diabetes generated by Dr. M. Paul Murphy’s lab (Niedowicz, Reeves et al. 2014). The 
combination of the two diseases results in additional pathologies such as aneurysms and 
strokes in addition to the ones that are characteristic of the parental AD mouse line.  
Similar to transgenic animals, and disease models described above, mutant mice 
such as knockouts also have the potential to add to our knowledge of the genes involved in 
sleep regulation. With this aim, I examined a large-scale knockout population phenotyped 
for their sleep-wake traits in addition to many other physiological aspects at the Jackson 
Laboratory (JAX) as part of the IMPC (International Mouse Phenotyping Consortium) 
project, as described next. 
The number of protein coding genes for the mouse genome stands at around 25,000. 
With developments in genome sequencing, and the advancement in gene targeting 
technology, it became feasible to knockout every single gene of the mouse genome. This 
led to the establishment of the International Knockout Mouse Consortium (IKMC) in 2007 
with the aim of functionally annotating the entire mammalian genome. The first phase 
involved creating ES (embryonic stem) cell lines for each targeted mouse gene (Abbott 
2010, Bradley, Anastassiadis et al. 2012). By 2011, over one-third of the mouse genes were 
established in ES cell lines. At this point, the second phase of the project, KOMP2 under 
the umbrella of IMPC began; an effort to turn these ES cell into “knockout mice” and then 
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comprehensively phenotype over 5000 knockout mouse lines generated in this phase 
(Brown and Moore 2012).  Our collaborator, The Jackson Laboratory, is one of the primary 
KOMP2 centers. Behavioral assays such as rotarod, holeboard exploration, and especially 
sleep, are unique to the JAX phenotyping pipeline. Such a large scale endeavor has many 
advantages over individual lab efforts, in part due to use of a standardized mouse 
background for the knockouts, standard protocols, and quality control. 
Traditional sleep analysis makes use of EEG/ EMG (Electroencephalogram/ 
Electromyogram) recordings which have been considered the “gold standard”. EEG/EMG 
techniques pose many limitations when it comes to recording rodents, especially on a large 
scale, as required for KOMP2. The system requires extensive surgery to fix the electrodes, 
recovery time, hooking up cables, and limited animal movement, in addition to labor 
intensive signal analysis (Flores, Flores et al. 2007). Alternative less invasive techniques 
like infrared beam breaking and wheel running have a lower correlation rate (70-80%) with 
sleep, depending upon the mouse strain under observation (Koteja, Garland et al. 1999). 
To overcome all these limitations, our lab designed the Piezoelectric system for non-
invasive higher throughput monitoring of sleep in rodents. 
The use of this system for phenotyping the sleep-wake traits has been central to my 
research projects. This non-invasive sleep-wake monitoring system consists of a 
Polyvinylidine Difluoride (PVDF) sensor pad placed on the cage floor which detects gross 
body movements of the animal to generate signals (Fig. 1). During sleep, rhythmic 3 Hz 
signals produced by breathing is the principal motion detected by the system in contrast to 
wakefulness which is characterized by high frequency and erratic movements which masks 
this breathing (Donohue, Medonza et al. 2008, Mang, Nicod et al. 2014). The system is 
capable of recording various sleep parameters including percent sleep, bout lengths, peak 
activity, activity onset and breath rate. Current efforts are directed toward adding more 
features and training the classifier based on correlation of Piezosystem recording with 
human observation and EEG. With these features, the system would be expanded to resolve 
sleep further into REM (Rapid Eye Movement) and NREM (Non-rapid eye movement), 
which would make the system more valuable for additional sleep assessments. In the future, 
the current data will be reanalyzed by these newer algorithms, but we can already determine 
sleep and wake with accuracy comparable to EEG/EMG.  
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To date, I have analyzed more than 6000 animals representing over 300 knockout 
lines, and more than 1800 control mice have been recorded. Around 20% of these knockout 
lines demonstrated altered sleep phenotypes, depending on the specific sleep traits assessed 
and the statistical approaches utilized. Some genes were found to specifically alter total 
sleep amounts or sleep fragmentation (sleep bout lengths) primarily in the light phase, 
others in the dark phase. Among controls and knockouts, males sleep slightly more than 
females in most but not all cases. The high hit rate seen in our study may also reflect that 
a high percentage of genes are expressed in the brain, and that many factors affect sleep. 
In addition, the same piezoelectric system also enabled us to look for altered breathing 
rhythms. Several genes were found to affect breathing variables as well. 
In summary, in the following chapters of this dissertation I describe in detail my 
studies to fill the gaps in our knowledge of the genetic regulators of sleep by examining a 
variety of mouse models. We utilized novel screening technology to phenotype sleep-wake 
traits and identified novel candidate genes that regulate sleep and perhaps sleep functions. 
Also, we evaluated mouse models of AD and Diabetic conditions for their sleep alterations 
that may be relevant for human AD and Diabetic diseases, and serve as a tool for the 
development of drugs to improve sleep and potentially slow the progression of disease. 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Chapter 2 Review-Large-scale sleep phenotyping projects in mice: 
application of high-throughput screens 
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Abstract 
 
Mouse models are an essential tool to dissect the genetic mechanisms that underlie 
complex behaviors such as sleep. A variety of genetic and genomic techniques are available 
to manipulate the mouse genome, and identify the genetic influences regulating sleep. 
Forward genetic techniques such as Quantitative trait loci (QTL) and mutagenesis screens 
are aimed at characterization of gene/s responsible for the phenotype in question. In 
contrast, reverse genetic methods may utilize knockout or other transgenic mice to 
ascertain the novel functions associated with a gene of interest. To fully exploit these 
available resources, and disentangle the pathways that regulate sleep, it is essential to 
implement robust phenotypic screens. In addition, for the detection of subtle phenotypes, 
analysis of a large number of animals is required. Conventional EEG/EMG is a popular 
sleep recording method, however, it is invasive and labor-intensive, and therefore not 
suitable for use in large-scale projects. There are many other alternative tools available 
such as video tracking, wheel running, light beam breaking, and piezoelectric systems. The 
choice for any of the particular alternative methods depend upon the specific needs of a 
research study. This paper reviews the large-scale projects as implemented in the field of 
sleep, and the advantages and shortcomings of the various phenotypic paraphernalia. 
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Introduction 
Sleep is a complex behavior that results from multiple underlying neuronal 
pathways, and is regulated (in part) by gene networks. In the last few decades, there has 
been increasing realization that sleep is critical for the overall well-being of an animal. 
Sleep has been suggested to be restorative in nature and critical in memory consolidation 
(Nishida, Pearsall et al. 2009, Walker 2009). In addition, it also has a role in modulating 
energy balance and immunity. Furthermore, sleep has been shown to facilitate clearance of 
toxic metabolites, including beta amyloid, a neuronal by-product of the APP protein that is 
a major constituent of the plaques in Alzheimer’s Disease (AD). Currently, more than 50 
million Americans are affected by sleep disorders or disturbances. These sleep deficiencies, 
in turn, are associated with a variety of health problems. For instance, inadequate sleep, 
which is becoming increasingly common due to the demands of a modern lifestyle, has 
been implicated in a variety of diseases including neurodegenerative and metabolic 
disorders (Knutson, Spiegel et al. 2007, Rothman and Mattson 2012, Suzuki, Miyamoto et 
al. 2012). Sleep apnea is linked to pathological conditions such as obesity, diabetes, 
hypertension, stroke, renal failure, and myocardial infarction (Shamsuzzaman, Gersh et al. 
2003). Some of these sleep problems arise as a result of a desynchronized biological clock, 
while others seem to be linked to disrupted physiological functions of sleep. Efforts aimed 
at improving sleep quality and treatment of sleep disorders are limited by our rudimentary 
knowledge of the functions of sleep and the mechanisms that regulate these functions. 
Identification of the genetic influences on sleep, and elucidation of the regulatory 
mechanisms at the molecular and biochemical level, would therefore be significant for the 
development of drugs targeting these regulators or other molecules that influence sleep and 
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wake. This review provides an overview of the large-scale genetic approaches undertaken 
to identify the sleep-related genes in mice, and also the scalable technology available to 
phenotype and characterize the sleep traits in these large mouse populations. 
Mouse-an animal model for sleep studies 
Human studies tend to be expensive and difficult to control in many cases. Given 
that there is 90% homology between the mouse and human genome (in the critical coding 
and gene regulatory regions), in addition to the strong conservation of most brain and 
physiological systems, the mouse has become the preferred animal model to emulate a 
wide variety of both normal and human pathological conditions. In areas relevant to sleep 
research, the mouse shares striking similarities to humans at the level of neural circuits 
and the neurotransmitters involved in sleep regulation, in addition to nearly 100% 
identity for critical circadian and sleep-related genes (at least among the few that are 
known). Furthermore, the availability of hundreds of inbred mice strains, and a wide-
array of genetic tools allow for easy manipulation of the mouse genome. Therefore, use 
of mice in parallel with well-established genetic resources can provide insight into the 
genetic determinants of sleep physiology.  
Forward Genetic Approaches 
QTL- mapping genomic loci  
A higher concordance of various sleep parameters and sleep architecture in mono- 
vs. di-zygotic twins provided early evidence for the genetic regulation of sleep (Stassen, 
Lykken et al. 1988, Ambrosius, Lietzenmaier et al. 2008, De Gennaro, Marzano et al. 
2008). Genetic studies conducted by Valatx, on several inbred, recombinant inbreds (RI) 
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and hybrid mice further strengthened the notion that sleep is under genetic control (Valatx, 
Bugat et al. 1972, Valatx 1978, Kitahama and Valatx 1980). Forward genetic techniques, 
which involve screening for sleep-related phenotypes, followed by scanning the genome 
in pursuit of genes affecting the trait in question, is one mechanism to determine the genetic 
components of sleep regulation. Traditional QTL analysis is one such phenotype-driven 
approach to identify genetic variants associated with complex traits. It typically involves 
crossing of two inbred strains that differ for the trait of interest. The F1 progeny is inter-
crossed, or back-crossed to one of the parents to generate an F2, which are then subjected 
to phenotypic assessment. In some cases, these crosses are followed by several generations 
of brother-sister matings to obtain homozygosity, and a set of defined Recombinant Inbred 
(RI) strains. Using the QTL approach, sleep-related genes such as Homer 1a, involved in 
recovery from glutamate-induced neuronal hyperactivity, Acads (acyl-coenzyme A 
dehydrogenase), which influences theta oscillations, and Rarb (Retinoic acid receptor 
beta), involved in long-term potentiation, were identified  (Tafti, Petit et al. 2003, Drager 
2006, Flores, Flores et al. 2007, Franken, Thomason et al. 2007, Maret, Dorsaz et al. 2007, 
O'Hara, Ding et al. 2007, Wisor, Striz et al. 2007). In a similar study, a QTL linked to phase 
advancement relative to dark onset, was mapped to chr 18 in “early runner” mice (Wisor, 
Striz et al. 2007). A comprehensive study by Winrow and colleagues, utilizing more than 
250- BL6 (BL6 and BALB/c) mice for the analysis of 20 sleep-wake traits, identified 52 
significant QTLs represented by 20 genomic loci (Winrow, Williams et al. 2009). In a 
follow up study, using pharmacological compounds, the investigators validated six of the 
candidate genes shortlisted previously- Chrm3, Chrna4, Drd5, Htr1d, Glp1r and Cacnali, 
for their role in regulating various aspects of sleep (Brunner, Gotter et al. 2011). 
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Furthermore, the same research group also narrowed down a QTL on chr 17, influencing 
REM sleep parameters, to the gene Ntsr1 by microarray expression analysis of over 28,000 
brain transcripts (Fitzpatrick, Winrow et al. 2012).  
A disadvantage of a typical QTL analysis is that the F2 progeny are unique, and 
thus require genetic mapping each time to identify the recombination patterns. There is 
also only a single individual mouse representing each F2 genotype, limiting the reliability 
of each phenotypic measure. Furthermore, even with accurate phenotyping, such crosses 
present limited mapping resolution, where a QTL can span several hundred genes (Flores, 
Flores et al. 2007, Franken, Thomason et al. 2007, Maret, Dorsaz et al. 2007, O'Hara, Ding 
et al. 2007, Wisor, Striz et al. 2007). Additionally, conventional crosses suffer from the 
issue of low genetic diversity present in most of the common laboratory mice as a result of 
historical development of inbred strains. In contrast, RI strains have fixed recombination 
patterns, and multiple mice of each genotype can be tested.  Since the genotype of each RI 
strain is fixed, they only need to be mapped once, and can then be used repeatedly by many 
investigators, in many different experiments, and can be replicated as often as desired in 
the future. Lastly, each RI strain represents multiple generations of recombinations, and 
thus has increased mapping power, although the limited number of RI lines has historically 
limited mapping resolution. To overcome these shortcomings of traditional QTL studies 
using RI lines, existing reference panels are being expanded as in the case of BXD strains, 
along with the development of new reference panels such as the Collaborative Cross (CC) 
using eight diverse parental strains (see below), and then using these same eight parental 
strains in Diversity Outbred (DO) mice (Peirce, Lu et al. 2004). 
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Collaborative cross for precision mapping 
CC and DO mouse resources exhibit a marked increase in genetic diversity, as 
much as 4 times that of the classical inbred mice, and can facilitate high resolution 
mapping, sometimes to the level of a single gene (Bradley, Anastassiadis et al. 2012, 
Gkoutos, Schofield et al. 2012, Schofield, Hoehndorf et al. 2012). The CC reference panel 
utilizes random crossing of eight founder strains. The founder strains are comprised of five 
traditional inbred laboratory strains and 3 wild-derived strains, which capture around 90% 
of the genetic diversity found in the laboratory inbred mice strains (Bradley, Anastassiadis 
et al. 2012, Gkoutos, Schofield et al. 2012, Schofield, Hoehndorf et al. 2012, Threadgill 
and Churchill 2012). These mice are being inbred to achieve a goal of generating 1000 
strains. CC mice provides another advantage- as with other RI strains, all lines are 
reproducible and, for each line, the genotyping is needed only once (Churchill, Gatti et al. 
2012, Svenson, Gatti et al. 2012, Threadgill and Churchill 2012).  
Diversity Outbred mouse- genetic panel with improved genetic diversity 
The Diversity Outbred panel is a heterogeneous stock of highly diverse mice from 
the same eight parental strains. They were designed to maximize genetic diversity similar 
to what is found in human populations. The DO founder mice were obtained from the 
incipient CC mice. Unlike the CC panel, the DO mice are maintained through random 
outbreeding rather than inbreeding, leading to additional recombinations and minimizing 
the chance of allelic loss. Random mating and the outbred nature yields a unique genetic 
constitution for each mouse and therefore non-reproducibility of DO animals (Churchill, 
Gatti et al. 2012, Svenson, Gatti et al. 2012, Threadgill and Churchill 2012). Thus, each 
mouse is required to be genotyped for the QTL analysis- a disadvantage compared to CC 
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mice. Overall mapping results from DO can be independently validated in CC lines 
(Bradley, Anastassiadis et al. 2012, Churchill, Gatti et al. 2012, Gkoutos, Schofield et al. 
2012, Schofield, Hoehndorf et al. 2012, Svenson, Gatti et al. 2012, Threadgill and 
Churchill 2012, Threadgill and Churchill 2012). Even though, CC and DO animals are yet 
to be utilized to their full potential, their successful application is already evident. One such 
noteworthy example of utilization of pre-CC (incipient CC mice) comes from a study 
conducted by Philip et al (Philip, Sokoloff et al. 2011). A QTL for peak activity after sleep 
deprivation, was mapped on chr 9, spanning 530 kb and harboring only 3 genes. In addition, 
another QTL, linked to sleep percentage during the dark phase, mapped to a genomic 
region on chr 7 representating a region of about39 genes. 
ENU mutagenesis- random point mutations of genes 
As the name suggests, ENU mutagenesis projects utilize ENU (N-ethyl-N-
nitrosourea), a chemical mutagen that randomly induces base substitutions in mouse 
spermatogonia. Mutagenized mice are then screened for a phenotype that shows significant 
deviation from the population mean for the trait of interest (Gondo 2010). Using this 
approach, the circadian genes, Clock and Rab3a in mice, and Per and Dbt in flies, were 
successfully isolated (Takahashi, Pinto et al. 1994, Vitaterna, King et al. 1994, Flores, 
Flores et al. 2007, Franken, Thomason et al. 2007, Maret, Dorsaz et al. 2007, O'Hara, Ding 
et al. 2007, Wisor, Striz et al. 2007). These genes further helped in discerning several other 
clock genes, such as Bmal1, Cry1,2, Per1,2,3, which regulate circadian and homeostatic 
aspects of sleep. Such successes lead to the initiation of many large-scale ENU mutagenesis 
projects (Gondo, Fukumura et al. 2009), targeting the entire mouse genome, each one of 
them focused on a phenotype of specific interest. Vitaterna and colleagues in their 
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mutagenesis screen, concentrated on behavioral and nervous system phenotypes, and 
reported 46 confirmed circadian mutants as of 2005 (Goldowitz, Frankel et al. 2004, 
Vitaterna, Pinto et al. 2006). In follow up studies, Ovtm was identified as a mutation in 
Fbxl3 gene, which was linked to a long circadian period (25.8 h) (Siepka, Yoo et al. 2007). 
In contrast, Prtm, a short circadian period (21.4 h) mutation, resulted from a loss-of-
function mutation in the Cry1 gene, and Psttm, another short period mutation (22.9 h) was 
traced to Fbxl21 gene (Siepka, Yoo et al. 2007, Yoo, Mohawk et al. 2013). 
A shortcoming of ENU mutagenesis is that it requires follow up with positional 
cloning for the identification of the causative gene, which is a difficult and time consuming 
process. However, with further advancement in genome sequencing, the mutations can now 
be identified in a cost and time efficient way. The process is still quite labor intensive in 
the case of mammals. Despite these difficulties and shortcomings, QTL studies and ENU 
mutagenesis are arguably our most powerful tools to find novel genetic pathways, as no a 
priori assumptions are made about the functions of any given gene. Given the pleiotropic 
nature of most genes, and our lack of knowledge regarding most of the 22,000 protein 
coding genes in mammals, these “blind” approaches are necessary.    
KOMP2- a large-scale, gene-driven approach 
              Reverse genetics, in contrast to forward genetics, is a genotype-driven approach 
that utilizes knockouts and other genetically altered mice to find novel functions associated 
with a gene of interest. It has helped further characterize, the roles of neurotransmitters and 
canonical circadian genes, such as Clock, Bmal and Npas (O'Hara, Jiang et al. 2017). 
Individual lab efforts are most often biased towards a small number of genes of interest, 
due to limitations of resources and expertise. These individual efforts at producing single 
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gene knockouts are also marked by heterogeneity of genetic background. To overcome 
these drawbacks, a more systematic and comprehensive project commenced in 2007, with 
the establishment of the International Knockout Mouse Consortium (IKMC). This large-
scale undertaking aims at generating single gene knockout ES cells for the entire mouse 
genome on the C57BL/6N background (Abbott 2010, Bradley, Anastassiadis et al. 2012). 
Knockout animals thus generated, are being comprehensively phenotyped for over 200 
physiological parameters as part of the Knockout Mouse Phenotyping Program (KOMP2) 
(Brown and Moore 2012). Many of the behavioral assays, such as rotarod and sleep 
assessments are unique to the Jackson Laboratory (JAX), one of the KOMP2 centers. 
KOMP2 has been instrumental in uncovering new candidate sleep genes. In collaboration, 
we have established a role for more than 50 genes, not implicated in sleep regulation 
previously (see Chapter 5).   
Recording systems for analysis of sleep 
EEG/EMG limitations 
             Phenotyping sleep-wake traits is an essential component of both forward and 
reverse genetic approaches towards a better understanding of sleep. The different sleep-
wake parameters that can be screened range from duration of sleep states (REM, NREM 
sleep), the number of such sleep bouts, and other variables such as sleep latency (time to 
fall asleep, which works better in humans that consolidate most sleep in one long sleep 
period at night, as opposed to the polyphasic sleep of mice). Sleep in all mammals is 
associated with distinct electrophysiological changes in brain activity. Traditionally, 
EEG/EMG techniques have been exploited for the measurement of these brain changes 
with high accuracy. However, for rodents which have smaller brains, it requires surgical 
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implantation of electrodes followed by recovery periods of many days, and labor intensive 
scoring. In addition, it entails tethering the animal to the EEG recording system that 
restricts the free movement of an animal. These drawbacks limit the application of EEG 
for high-throughput behavioral studies that require large numbers of mice for discerning 
phenotypic effects. Multiple, non-invasive, alternative systems have been developed in the 
past few decades for the assessment of sleep-wake related behaviors. There are several 
automated recording systems available, such as those based on monitoring of activity or 
video recordings which can assess behaviors related to sleep, and also some variations to 
make EEG/EMG easier, as discussed next.    
Telemetry- alternative EEG/EMG method to record sleep  
           Telemetry provides another way of doing EEG/EMG, which does not require 
animals to be tethered for data acquisition. It allows recording animals under a variety of 
conditions such as group housing, as well as more enriched environments. Furthermore, it 
can measure various physiological parameters in addition to sleep, such as body 
temperature and activity of an animal. Similar to typical EEG/EMG recordings, it still 
requires surgical implantation of electrodes as well a transmitter. Typical radio transmitters 
tend to be relatively heavy and big for the size of the skull of a mouse (for instance, 3.9 g 
at a volume of 1.9 cc for DSI PhysioTel EA-F20 and ETA-F10; 
https://www.datasci.com/products/implantable-telemetry/mouse-(miniature)). However, 
the newer generation of these systems can be as light as 1.4 g, which is still extremely 
heavy and causes problems for typical inbred strains weighing 20-30g. There are other 
improvements being made to this system. Recently, a wireless telemetry system was 
developed that does not require anchor screws to affix the system to the skull, but just the 
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burr holes, and can be used in young pups as well (Zayachkivsky, Lehmkuhle et al. 2013).  
However, despite these improvements, these telemetry systems typically have much higher 
noise and poorer sleep scoring than traditional cabled EEG/EMG systems.   
Minimally-invasive approach 
           A less-intensive surgery method based on locomotor activity, was developed by 
Storch et al (Storch, Hohne et al. 2004). This method requires implanting small magnets 
subcutaneously near neck muscles of mice. Mice activity is characterized by magnet 
movement relative to a sensor plate placed beneath the cage. The system can detect 
sleep/wake quantitatively with limited accuracy, in addition to activities such as grooming 
and rearing. However, it cannot discern quiet rest, or sub-stage sleep into REM and NREM. 
Additionally, it has a low resolution, and still requires surgery which makes the system 
difficult for higher throughput studies (e.g. more than 200 mice). 
Non-invasive approaches 
         As described above, both EEG/EMG and telemetry involves surgical implants, which 
can affect the natural behavior of an animal. In addition, these methods are expensive as 
well, and thus not suitable for assessment of a large number of mice. To address these 
deficiencies, a number of other, non-invasive devices for sleep phenotyping have been 
developed. One such scoring system designed by Pack et al utilizes object recognition 
algorithms in combination with video-scoring and infrared beam breaks (Pack, Galante et 
al. 2007). The characterization of sleep and wake was based on the investigators’ premise 
that an activity of more than 40s can be classified as sleep. This setup showed high 
correlation with EEG assessments. Fisher et al also utilized video tracking- based on 
locomotor analysis, which shows high correlation with EEG/EMG assessment of sleep-
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wake, however, it cannot discern sleep architecture- REM and NREM sleep, similar to the 
system developed by Pack et al (Fisher, Godinho et al. 2012). There are other limitations 
associated with video-based devices such as adjustment of camera angle, and need for 
proper illumination at all times. There are other systems available as well, such as infrared 
beam breaking which is limited to detecting gross body movements. It cannot distinguish 
quiet rest from sleep, and also does not work well when the mouse does not change its 
location frequently. 
         Respiratory patterns have also been used as an alternative to EEG/EMG, as in the 
case of a system developed by Zeng and colleagues (Zeng, Mott et al. 2012). They utilized 
a Doppler radar system, and support vector machine, a supervised learning system, to 
classify different vigilance states. The system has high classification accuracy for 
wakefulness and NREM (91% and 85% respectively) but low accuracy for REM sleep 
(~70%).  
        PiezoSleep- a novel, non-invasive and high-throughput system, is based on periodic 
signals generated during respiration. It utilizes a motion sensor- piezoelectric film, placed 
at the bottom of the cage floor, which transforms the pressure variations into electrical 
signals. During sleep, the prominent movement is from breathing, in contrast to 
wakefulness that is characterized by more erratic signals is the basis of discerning sleep 
and wakefulness by this system (Flores, Flores et al. 2007, Donohue, Medonza et al. 2008, 
Mang, Nicod et al. 2014). The system demonstrates a classification accuracy of over 90% 
for sleep and wakefulness compared to traditional EEG/EMG (Donohue, Medonza et al. 
2008, Mang, Nicod et al. 2014). Additionally, the system due to its highly sensitive nature 
can discriminate quiet wake from sleep, and also detect short arousals which almost all 
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other non-invasive systems fail to. This automated system is equipped to record a variety 
of sleep parameters- sleep percent across 24h, dark and light phase, and bout length across 
24h, dark and light phase. The systems’ additional hourly data assessment feature finds its 
use in time-sensitive studies such as those involving sleep deprivation, or effect of dosage 
of drugs as exemplified by my research project on 5XFAD, as described in chapter 3 (Sethi, 
Joshi et al. 2015). It has also been equally effective, as validated by IR camera and 
EEG/EMG in recording sleep for larger rodents such as Spiny mice.  
           Recently, the systems capabilities were enhanced further, and it integrated 
assessment of breath rate, a supplemental tool in determining aberrant sleep physiology in 
animals. The system was recently tested for its assessment of sub-stages of sleep, and was 
found to have a high classification rate for wake and NREM sleep but underestimated REM 
sleep (Yaghouby, Donohue et al. 2016). With further improvements in its algorithm, 
classification of REM sleep as well is expected to improve in near future. In its current 
form, the piezosystem has been significant in identifying more than 50 sleep-related genes, 
and several other genes affecting breath rate in mice, as part of KOMP2, an ongoing large-
scale endeavor, within a short time span (Chapter 5). Thus, PiezoSleep, an important 
component of KOMP2, contributed massively to such unprecedented success in the field 
of sleep. A pre-CC study, also utilized this system and found reasonable success in finding 
QTLs affecting a variety of sleep parameters (Philip, Sokoloff et al. 2011).  
Conclusion 
 No single technique of gene analysis is complete by itself and has limitations of its 
own. EEG/EMG technique is invasive, and can alter the natural behavior of an animal, and 
on other hand, most of the other, non-invasive alternatives fail to record sleep measures 
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such as NREM delta waves, a measure of sleep intensity. For high-throughput behavioral 
studies, the relatively inexpensive, non-invasive alternatives, such as PiezoSleep can serve 
well as a first pass. Later, the animals with phenotype of interest can be followed with 
EEG/EMG if needed, for more comprehensive sleep phenotyping. This 2-step process can 
reduce time and efforts by many fold. Further improvements in existing techniques as in 
case of PiezoSleep, and also ongoing development of new strategies will equip us better at 
the task of annotating genes without the need of EEG/EMG eventually. Large scale 
phenotype- or gene- driven approaches are invaluable tools to unravel novel sleep-related 
genes, and identify novel pathways depicting relationship among them by utilizing various 
bioinformatics tools. Furthermore, different approaches can complement each other and 
reveal further the association between protein domains of a gene and their functions. In 
summary, advancements in sleep phenotyping techniques in parallel with systematic 
phenotyping pipelines is critical in identifying novel candidate genes underlying sleep 
modulation.  
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Chapter 3 Increased fragmentation of sleep-wake cycles in the 5XFAD 
mouse model of Alzheimer’s disease 
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Abstract 
            Sleep perturbations including fragmented sleep with frequent night-time 
awakenings and daytime naps are common in patients with Alzheimer’s disease (AD), and 
these daily disruptions are a major factor for institutionalization. The objective of this study 
was to investigate if sleep-wake patterns are altered in 5XFAD mice, a well-characterized 
double transgenic mouse model of AD which exhibits an early onset of robust AD 
pathology and memory deficits. These mice have five distinct human mutations in two 
genes, the amyloid precursor protein (APP) and Presenilin1 (PS1) engineered into two 
transgenes driven by a neuron specific promoter (Thy1), and thus develop severe amyloid 
deposition by 4 months of age. Age matched (4-6.5 months old) male and female 5XFAD 
mice were monitored and compared to wild-type littermate controls for multiple sleep traits 
using a non-invasive, high throughput, automated piezoelectric system which detects 
breathing and gross body movements to characterize sleep and wake. Sleep-wake patterns 
were recorded continuously under baseline conditions (undisturbed) for 3 days and after 
sleep deprivation of 4 hours, which in mice produces a significant sleep debt and challenge 
to sleep homeostasis. Under baseline conditions, 5XFAD mice exhibited shorter bout 
lengths (14% lower values for males and 26% for females) as compared to controls 
(p<0.001). In females, the 5XFAD mice also showed 12% less total sleep than WT 
(p<0.01). Bout length reductions were greater during the night (the active phase for mice) 
than during the day, which does not model the human condition of disrupted sleep at night 
(the inactive period). However, the overall decrease in bout length suggests increased 
fragmentation and disruption in sleep consolidation that may be relevant to human sleep. 
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The 5XFAD mice may serve as a useful model for testing therapeutic strategies to improve 
sleep consolidation in AD patients. 
 
Key words:  sleep, sleep homeostasis, amyloid beta, diurnal rhythm, sleep fragmentation 
Introduction 
            Alzheimer’s disease (AD), which is characterized by accumulation of extracellular 
amyloid beta (Aβ) plaques and intra-neuronal hyperphosphorylated neurofibrillary tau 
tangles in the brain, is the most common form of dementia (Glenner and Wong 1984). 
Aside from severe cognitive deficits, approximately 25 to 40% of AD patients also display 
profound circadian rhythm and sleep-wake disturbances, which may precede overt 
cognitive impairments (Carpenter, Strauss et al. 1996, Moran, Lynch et al. 2005, Snyder, 
Nong et al. 2005). These disturbances include fragmented sleep, frequent nighttime 
awakenings, and excessive daytime sleepiness (Prinz, Peskind et al. 1982, Bliwise 2004, 
Bliwise, Mercaldo et al. 2011). Altered sleep architecture in AD includes reduced rapid 
eye movement (REM) and slow wave (SWS) sleep in addition to increased latency to REM 
sleep (Prinz, Peskind et al. 1982, Bliwise, Tinklenberg et al. 1989, Perry, Walker et al. 
1999, Stevenson and Schildberger 2013). Fragmented sleep, which is also common in 
many other pathological conditions including Parkinson’s Disease, Diffuse Lewy Body 
Disease (DLBD), sleep apnea, and neuromuscular disorders, has wide spread consequences 
ranging from excessive daytime sleepiness to impaired memory consolidation (Kimoff 
1996, Dauvilliers 2007, Deschenes and McCurry 2009, Rolls, Colas et al. 2011). Recent 
studies suggest that reduced slow wave sleep, which has been shown to have restorative 
functions, might be the contributing factor to this impaired memory consolidation (Nishida, 
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Pearsall et al. 2009, Walker 2009). However, there is still much debate regarding the 
contribution of different sleep stages in the consolidation of different type of memories, 
with some data supporting a role for all stages of NREM in declarative memory and a 
greater role for REM in non-declarative memory (Tucker, Hirota et al. 2006, Marshall and 
Born 2007, Nishida, Pearsall et al. 2009, Diekelmann and Born 2010).  
            In regard to circadian system dysfunction, Saitlin et al found that AD subjects have 
reduced locomotor activity and phase delays of approximately four hours in their activity 
rhythms and three hours for the core body temperature rhythm compared to healthy elderly 
subjects (Satlin, Volicer et al. 1995). Often, AD patients also display “sundowning”; a 
behavioral state characterized by increased aggressiveness, restlessness and anxiety seen 
towards the afternoon and evening hours (Vitiello, Bliwise et al. 1992). These changes in 
sleep and circadian rhythms, which correlate positively with the degree of progression of 
AD, not only affect the quality of life of patients and their care givers but also constitute 
one of the major factors for institutionalization (Pollak and Perlick 1991, Vitiello, Poceta 
et al. 1991).   
            Aggregation of amyloid beta (Aβ) in the brain has been implicated in sleep 
perturbations as well as in the pathogenesis of AD (Hardy and Higgins 1992, Hardy and 
Selkoe 2002). Various findings suggest that Aβ aggregation, as indicated by reduced 
cerebrospinal fluid (CSF) Aβ42 levels, begins as early as 15 years prior to the appearance 
of clinical symptoms  (i.e. the preclinical stage) (Morris and Price 2001, Perrin, Fagan et 
al. 2009, Sperling, Aisen et al. 2011, Fitzsimmons and Bertram 2013). Even in 
asymptomatic individuals, Aβ is associated with neural dysfunction of the brain networks 
subserving memory formation (Sheline, Raichle et al. 2010). Among cognitively 
25 
 
unimpaired individuals, those with higher levels of Aβ accumulation had poorer sleep 
quality and shorter sleep duration compared to controls without Aβ plaques (Anafi, 
Pellegrino et al. 2013, Aoyama and Nakaki 2013, Dyakonova and Krushinsky 2013, 
Fitzsimmons and Bertram 2013, Ju, McLeland et al. 2013, Malkki 2013, Möller-Levet, 
Archer et al. 2013, Simon, Greenaway et al. 2013, Spira, Gamaldo et al. 2013, Stevenson 
and Schildberger 2013, Vagelatos and Eslick 2013, Yoo, Mohawk et al. 2013, Ju, Lucey et 
al. 2014).  
            Various studies performed in mouse models of AD also indicate an association 
between sleep perturbations and AD pathogenesis. Using microdialysis, Kang et al 
demonstrated that young Tg2576 mice (a model of AD), and wild type mice (C57BL6) 
have diurnal oscillations of brain interstitial fluid (ISF) Aβ, with higher levels during the 
active phase (night-time) (Kang, Lim et al. 2009). In aged APPswe/PS1δE9 mice with 
prominent Aβ plaques, sleep is disrupted as well as ISF Aβ diurnal rhythm is lost (Bertram, 
Rook et al. 2011, Roh, Huang et al. 2012). Further, sleep deprivation increases ISF Aβ, 
which decreases during sleep recovery (Kang, Lim et al. 2009, Bertram, Rook et al. 2011, 
Roh, Huang et al. 2012). Similar diurnal oscillations were found for CSF (cerebrospinal 
fluid) Aβ in healthy human subjects, with higher Aβ levels in day and reduced levels at 
night (Kang, Lim et al. 2009). These studies suggest that sleep loss accelerates the Aβ 
deposition and therefore sleep alterations may serve not only as an early marker of AD but 
also raise the possibility that improved sleep could slow progression of the disease. The 
extent to which the changes in sleep-wake patterns contribute to or are the result of AD 
progression is poorly understood. Because studies in AD patients are difficult and 
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expensive, an animal model displaying sleep alterations that mimic those found in AD is 
necessary.    
            Our present study aimed at investigating whether 5XFAD mice (MGI: 3693208), a 
well-characterized, double transgenic model of familial, early onset AD, show alterations 
in sleep-wake patterns. These mice have five distinct human mutations: three in the 
amyloid precursor protein (APP) namely Swedish, Florida and London mutations 
(K670N/M671L, I716V, V717I) and two in the Presenilin1 protein (PS1), i.e., mutations 
M146Ll and L286V engineered into two transgenes driven by a neuron specific promoter 
(Thy1). Each of these PS1 and APP mutations increase Aβ42 production but when present 
together act additively to bring about an excessive Aβ42 burden and hence early onset and 
aggressive AD pathology (Citron, Westaway et al. 1997, Eckman, Mehta et al. 1997, 
Citron, Eckman et al. 1998, Oakley, Cole et al. 2006, Ohno, Chang et al. 2006). These mice 
thus develop severe intraneuronal Aβ42 at an early age of 1.5 months, amyloid deposition 
at 2 months, and loss of synapses around 9 months of age (Oakley, Cole et al. 2006, Ohno, 
Chang et al. 2006). As well as aggressive neuropathology, 5XFAD mice exhibit memory 
deficits as early as 4-6 months of age, in a range of behavioral assays such as Y maze, 
Morris water maze, contextual fear conditioning, auditory trace fear conditioning 
paradigm, and olfactory H maze (Oakley, Cole et al. 2006, Ohno, Chang et al. 2006, Ohno 
2009, Devi, Alldred et al. 2010, Devi and Ohno 2010, Girard, Baranger et al. 2013). Since 
the 5XFAD mice exhibit well characterized, early onset AD-like neuropathological 
changes and cognitive impairments, the current study investigated whether these mice also 
exhibit sleep alterations similar to those reported in AD patients. Since AD affects men and 
women, we included both male and female 5XFAD mice in our study. More women are 
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known to have AD compared to men, possibly because of longer life expectancy in women 
(Hebert, Scherr et al. 2001) or due to hormonal alterations late in life (Morinaga, Ono et 
al. 2011, Barron and Pike 2012, O'Hagan, Wharton et al. 2012, Anaclet, Ferrari et al. 2014, 
Bhattacharya, Haertel et al. 2014, Civelek and Lusis 2014, Ju, Lucey et al. 2014, Lan, Zhao 
et al. 2014, Lim, Ellison et al. 2014, Lim, Gerstner et al. 2014, Mang, Nicod et al. 2014, 
Niedowicz, Reeves et al. 2014, Webster, Bachstetter et al. 2014). In this study, we analyzed 
the following sleep traits: sleep during the day and night, sleep bouts during the day and 
night under baseline conditions, and then examined sleep behavior again after 4 hour sleep 
deprivation in an effort to find if 5XFAD mice model some aspects of the sleep alterations 
reported in human AD patients.    
Experimental procedures 
Animal and housing conditions 
            This study utilized individually housed 5XFAD mice (males: N=10; females: N=7) 
and wild type mice (males: N=7; females: N=11) for baseline recording and sleep 
deprivation protocol was applied on 5XFAD (males: N=9; females: N=6) and wild type 
mice (males: N=6; females: N=11) of 4-6.5 months of age (lost data for few mice because 
of system failure), obtained from a breeding colony maintained at University of Kentucky. 
The original 5XFAD stock was provided by The Jackson Laboratories. Originally, 5XFAD 
were generated on B6/SJL background as previously described (Oakley, Cole et al. 2006, 
Ohno, Chang et al. 2006). This mouse model co-expresses three APP (Swedish: 
K670N/M671L, Florida: I716V and London mutation: V717I) and two PS1 human familial 
mutations (M146L, L286V) under the regulation of neuron-specific murine Thy1 
promoter. These mice show intracellular Aβ accumulation at the age of 1.5 months. Plaque 
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deposition can be detected since 2 months of age; first appearing in deep layers of cortex 
and subiculum and eventually spreading to most of the cortex, subiculum and 
hippocampus. Apart from neuroinflammation, these mice also present neuronal loss, a 
characteristic often missing in most of the other transgenic mouse models of AD (Oakley, 
Cole et al. 2006, Ohno, Chang et al. 2006, Jawhar, Trawicka et al. 2012, O'Hagan, Wharton 
et al. 2012, Eimer and Vassar 2013, Girard, Baranger et al. 2013, Ju, McLeland et al. 2013, 
Lim, Yu et al. 2013, Malkki 2013, Sterniczuk, Theou et al. 2013, Vagelatos and Eslick 
2013, Ju, Lucey et al. 2014). In 5XFAD mice, synaptic degeneration as evident from 
reduced expression of synaptic markers is seen commencing at the age of 4 months, the 
same age at which various hippocampal- and cortical- dependent memory impairments 
have been observed (Oakley, Cole et al. 2006, Ohno, Chang et al. 2006, Ohno 2009, Devi, 
Alldred et al. 2010, Devi and Ohno 2010, Girard, Baranger et al. 2013).  The 5XFAD mice 
have also been reported to have lower body weight (~10%) than wild-type controls at 6-7 
months of age (Jawhar, Trawicka et al. 2012, Bhattacharya, Haertel et al. 2014); whether 
this results from changes in food intake or metabolism has not been reported, to the best of 
the authors’ knowledge.  
             In the current study, all mice were exposed to an alternating light (L): dark cycle 
(D), with lights on from 7 AM to 7 PM. Food (pellets) and water were provided ad libitum. 
All experimental procedures (described below) were approved by the Institutional Animal 
Care and Use Committee at the University of Kentucky and are consistent with the Institute 
of Laboratory Animal Resources Guide for Care and Use of Laboratory Animals, 8th 
edition.  
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Sleep recording with piezoelectric system  
            Sleep and wake states were determined using a piezoelectric system, as described 
previously (Flores, Flores et al. 2007, Donohue, Medonza et al. 2008). The system is 
comprised of plexiglass cages lined with piezoelectric films across the bottom that detect 
pressure variations. For all sleeping postures of the mouse, pressure variations from 
breathing are detected. Sleep states are characterized by quasi-periodic signals with low 
variations in amplitude, whereas wakefulness and rest states are characterized by irregular 
transient and high amplitude pressure variations corresponding to conscience body 
movements and weight shifting. Signal features sensitive to the differences between the 
sleep and wake states are extracted from the short-time pressure signal segments, and 
classification is automatically performed every 2 seconds. Data collected from the piezo 
system were binned over specified time periods (e.g. 5 minutes, 1 hour) using a rolling 
average of the percent sleep, as well as binned by length of individual bouts of sleep and 
the mean bout lengths were calculated. The sleep bouts were computed as the duration of 
contiguous sleep states. Sleep bouts were terminated by any arousal more than 2 seconds 
in duration. When counting all short arousals and short sleep bouts, average bouts in mice 
are typically less than 1 minute (Franken, Malafosse et al. 1999). The piezo system has 
been validated with EEG and human observations and demonstrates a classification 
accuracy of over 90% (Donohue, Medonza et al. 2008, Mang, Nicod et al. 2014).   
            Prior to sleep recording, the mice were acclimated in the plexiglass cages for 2-4 
days. For the baseline measurements, mice were recorded for 3-5 days, during which time 
the mice were undisturbed except for monitoring once daily for food and water. The 
parameters that were analyzed under baseline conditions included total sleep time averaged 
over 24 h, average percentage of sleep across day (light phase), average percentage of sleep 
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across night (dark phase), average sleep bout length (across 24 hours, day and night), 
activity onset defined as the time relative to dark onset when the first sharp increase in 
percent wake states computed over a 2-hour sliding window occurs between 3 hours before 
and 3 hours after dark onset, on each day. This is typically the largest increase in this period, 
increasing from below 40% wake time to over 80% wake time. Diurnal wake ratios are 
related to the differential wake percentages during the light and dark phases, and are 
defined as the ratio of maximum wake-state percent in the dark phase to the minimum 
wake-state percent in the light phase, where percentages are computed over 3-hours 
intervals. Activity onset, as defined above, was also used a phase marker for the daily 
rhythm of sleep and activity.   
             For the second part of the study, the mice were sleep deprived for 4 hours 
beginning either at 8 or 9 AM. Sleep deprivation was accomplished by transferring the 
mice to novel cages. To keep the mice awake, nestlets (squares of cotton fibers that mice 
shred to build nests) and other novel objects were introduced to the cages, and cages were 
tapped gently when mice appeared ready to sleep. As the four hours progressed, more 
action was needed to keep mice awake. First, cage lids were gently removed and then 
replaced, providing additional air flow and olfactory and visual stimulation. If this failed 
to arouse the mice, then they were gently manipulated to induce movement. At the end of 
the sleep deprivation protocol, the mice were transferred back to their piezoelectric cages 
to continue monitoring sleep bout lengths and total amount of sleep.  
Data analysis  
            The data were analyzed using SPSS statistics software version 20.0. Group data 
was analyzed by a general linear model of analysis of variance (ANOVA) for the baseline 
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studies. Initial assessment showed that males and females differed significantly from each 
other (not shown), consequently all the data were pooled and analyzed separately for the 
two sexes. Before conducting ANOVA, the data were tested for normal distribution and 
homogeneity of variance. For all of the sleep-wake parameters under consideration (listed 
above), P-value less than 0.05 were considered significant. Genotype was considered as an 
independent variable and the parameter under observation as the dependent variable. 
Hourly sleep percentage and bout length after 4 hour of sleep deprivation were analyzed 
with mixed ANOVA. 
Post-mortem genotyping 
            After the sleep recording was complete, the mice were euthanized by CO2 
inhalation and decapitation. From dissected brains, cortex was preserved at -70° C for 
genotyping. Genotyping was conducted using conventional PCR or/and three-step serial 
extractions of Aβ with sequentially increasing denaturing conditions followed by 
quantification with a two-site (sandwich) ELISA as described previously (Kukar, Murphy 
et al. 2005, McGowan, Pickford et al. 2005, Beckett, Niedowicz et al. 2010, Bruce-Keller, 
Gupta et al. 2011). The primers used are listed here: 
PCR Primer Sequence (5' to 3') 
 
APP Forward: AGAGTACCAACTATGACTACG 
APP Reverse:  ATGCTGGATAACTGCCTTCTTATC 
PS1 Forward:  ATGACAGAGTTACCTGCACCGTTG 
PS1 Reverse:   CTGACTTAATGGTAGCCACGACCA  
Results  
Sleep under baseline (undisturbed) conditions 
            Sleep-wake patterns were monitored in 5XFAD mice in order to determine the 
effects of Aβ42 overexpression. Statistical analyses (ANOVA) showed that 5XFAD male 
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mice did not differ from control littermates in the average total amount of sleep [ i.e., sleep 
across 24h (F(1,49)= 1.11, P=0.298)]; daytime sleep (F(1,49)=0.48, P=0.493), or nighttime 
sleep (F(1,49)=0.63, P=0.431) (Figure 1 and Table 1)]. In the case of females, 5XFAD mice 
showed a significant reduction in average total amount of sleep (F(1,52)=7.09, P=0.01) as 
well as nighttime sleep (F(1,52)=7.54, P=0.008), compared to wild-type mice (Figure 1). 
Additionally, average total sleep bout length (across 24h) was reduced in 5XFAD mice of 
both the sexes; 14% in males and 26% in females (Figure 1). The decreased bout length in 
5XFAD mice was observed during both the light phase and the dark phase (male mice: 
average bout length across 24h, F(1,49)=12.12, P=0.001; daytime, F(1,49)=7.97, P=0.007; 
nighttime, F(1,49)=8.77, P=0.005) and for female mice: average bout length across 24h, 
F(1,52)=24.18, P<0.001; daytime, F(1,52)=10.48, P=0.002; nighttime, F(1,52)=34.48, P<0.001).   
 
 
Parameter Wild type          5XFAD Wild type          5XFAD 
  Male Male Female Female 
Percent sleep day 56.5±0.8 55.7±0.8 55.1± 1.4 52.5± 0.8 
Percent sleep night 27.1±1.5 25.4±1.4 23.2± 1.3 17.2± 1.8** 
Percent sleep total (24h) 41.8±0.8 40.6±0.8 39.1± 1.1 34.8± 0.9* 
Bout length day 60.4±2.0 54.0±1.3** 65.6± 2.1 54.0± 3.0** 
Bout length night 46.1±2.5 37.0± 1.9** 33.7± 1.2 21.0± 1.9*** 
Bout length total (24h) 54.5±1.9 46.9±1.2** 50.4± 1.2 39.9± 2.0*** 
Activity onset  0.11±0.13 0.13±0.18 0.14±0.17 0.02±0.99 
 
Values represent means ± SEM. *: P < 0.05; **P <0.01, ***P < 0.001.  All comparisons are 
between WT and 5XFAD of the same sex.   
Table 1 Effect of genotype on sleep wake traits under baseline conditions 
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Figure 1 Sleep-wake patterns in 5XFAD and WT littermates under baseline conditions. Average 
percent sleep across 3 consecutive days analyzed over (A) 24 hours, (B) dark phase, and (C) light 
phase. Female but not male 5XFAD mice show reduction in sleep duration across 24 h and during 
the dark phase.  (D to F) depicts average bout length in seconds (s) over (D) 24 h (E) dark phase, 
and (F) light phase.  5XFAD mice of both sexes had shorter average bout lengths across all phases 
in both the sexes. Values represent means ± SEM. *: P < 0.05; **P <0.01, ***P < 0.001 
 
A                D 
   
B                E 
   
C          F 
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There was no apparent genotypic difference in the sleep wake profile for both the 
sexes compared to their control littermates (Figure 2). Both WT and 5XFAD mice had 
activity onsets closely coinciding with dark onset, suggesting that there was no apparent 
change in phase of the daily sleep-wake rhythms. Similarly, there was no change in the 
peak activity or diurnal wake ratio. For males, the diurnal wake ratio (mean + S.E.M.) was:  
WT, 2.67±0.21, and 5XFAD, 2.93±0.34. For females, the diurnal wake ratio (mean + 
S.E.M.) was:  WT, 4.46±0.33 and 5XFAD, 4.38±0.58. The higher ratio in females was due 
to less sleep during the dark period, as is typical for female mice.   
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A. 
 
B. 
 
C. 
 
D. 
 
Figure 2 Representative sleep-wake profiles for 5XFAD mice (A and C) and control littermates (B 
and D). The percent wake plotted on the Y axis is represented as a sliding average over a 2 hour 
window. Hours of recording are plotted on the X-axis where 0 represents the midnight of day 1. 
Broken vertical lines demarcate the dark phase, which is also indicated by a heavy horizontal black 
line at the bottom.  
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Sleep after 4-h sleep deprivation 
           Percent of sleep and bout length (dependent variables) in the 6 hours immediately 
after sleep deprivation (4 hours) was compared between wild type and transgenic (5XFAD) 
groups using mixed ANOVA model with the genotype as the between-subjects variable 
and time (6 time points) as the repeated measure (or within subject variable). There was no 
interaction between genotype and time for bout length (males: F (5,65)=0.49,  P=0.782; 
females: F (5,75)=0.580, P=0.715) and sleep duration (males: F (5,65)=1.55,  P=0.186; 
females: F (5,75)=0.922, P=0.471) after sleep deprivation for either sex (Table 2 and Figure 
3). 
 
Percent sleep post-SD      
 1st h 2nd h 3rd h 4th h 5th h 6th h 
WT Male 24.4±6.2  65.9±7.3 46.9±8.5  
 
30.0±7.5 41.4±10.3 10.4±8.2 
5XFAD Male                                             24.9±5.1 49.1±5.9 49.8±7.0 39.9±6.1 35.3±8.4  23.7±6.7 
WT Female 60.4±5.9  67.4±4.2 67.8±4.6 62.8±4.2 54.2±6.2 59.3±4.1 
5XFAD Female                                             50.3±8.1 57.4±5.7 54.3±6.3 56.3±5.7 55.6±8.5 42.5±5.6 
       
    Bout length (seconds) post-SD     
 1st h 2nd h 3rd h 4th h 5th h 6th h 
WT Male 22.9±4.5  55.9±6.7 51.6±10.3  37.5±7.0 48.8±23.3 22.1±10.5 
5XFAD Male                                             20.5±3.7 36.7±5.5 43.5±8.4 34.9±5.7 50.6±19.0  25.9±8.6 
WT Female 42.5±5.1  50.4±4.7 52.0±5.1 48.4±5.3 45.0±4.6 50.5±5.5 
5XFAD Female                                             45.4±6.9 44.2±6.4 46.6±6.9 43.7±7.1 37.7±6.3 39.6±7.4 
Values represent mean ± SEM 
 
Table 2 Effect of genotype on sleep wake traits after sleep deprivation (SD) 
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Discussion  
 
            Sleep has become a key avenue of research in the quest to find mechanisms 
underlying Alzheimer’s disease and development of effective therapeutics. It plays a 
variety of roles crucial to maintaining optimal brain functions and has been found to be 
           A        B 
                  
 
           C                                         D 
                  
Figure 3 Comparison of the sleep-wake patterns of WT and 5XFAD mice after a sleep deprivation of 4 h. 
Average percent sleep in males (A),  females (B), and average bout length in male (C) and female mice (D) 
was analyzed for 6 h of the recovery period. No genotype difference was found using Mixed ANOVA. 
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closely linked to AD pathology. One source of evidence comes from a study where 
improved sleep lowered the risk of AD in people with at least one APOE Ɛ4 allele (Lim, 
Yu et al. 2013, Simon, Greenaway et al. 2013). This finding is consistent with other studies 
showing that AD patients frequently have poor quality of sleep, even before the onset of 
clear symptoms. Poor sleep may be one factor contributing to their compromised cognition 
since sleep plays a critical role in learning, memory, and other brain functions (Durmer and 
Dinges 2005, Killgore, Balkin et al. 2006, Killgore, Rupp et al. 2008, Ker, Edwards et al. 
2010, Mongrain, Hernandez et al. 2010, Rillich, Schildberger et al. 2011, Bertram and 
Rook 2012, Callander, Bolton et al. 2012, Reichert and Gerhardt 2013).  In a recent study, 
Lim and colleagues found that loss of neurons  in the intermediate nucleus, a proposed 
homologue of the rodent ventrolateral preoptic nucleus (VLPO), is a potential contributing 
factor for the fragmented sleep seen in older individuals including Alzheimer’s patients 
(Lim, Ellison et al. 2014).  
            This study aimed at identifying sleep-wake alterations in the AD mouse model- 
5XFAD, that recapitulates certain features of the human AD condition and may help in 
understanding the underlying mechanisms of this disease. Both male and females 5XFAD 
mice belonged to the age group, 4 to 6.5 months, which shows many of the pathological 
characteristics of AD including accumulation of intraneuronal Aβ, cerebral plaque 
deposition, gliosis, synaptic degeneration, neuronal loss, and memory deficits (Oakley, 
Cole et al. 2006, Ohno, Chang et al. 2006, Jawhar, Trawicka et al. 2012, O'Hagan, Wharton 
et al. 2012, Eimer and Vassar 2013, Girard, Baranger et al. 2013, Ju, McLeland et al. 2013, 
Lim, Yu et al. 2013, Malkki 2013, Sterniczuk, Theou et al. 2013, Vagelatos and Eslick 
2013, Ju, Lucey et al. 2014). Early onset of the robust pathology seen in these mice 
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attributable to the incorporation of five additive mutations lead to increased total Aβ 
production which makes the 5XFAD mouse a useful experimental tool for investigating 
the effects of increased Aβ42 levels which is thought to be one of the key factors involved 
in disease progression. Also, only a handful of previous studies of AD mouse models have 
included both sexes or investigated sleep fragmentation.  
            Our findings show that under baseline conditions, average length of sleep bouts was 
reduced in both male and female 5XFAD mice. In addition, female mice also had 
significant reduction in total sleep time averaged over 3 days and sleep occurring during 
the dark periods. However, male mice did not differ from control littermates in their sleep 
duration. In contrast to initial expectations, reductions in bout length were found to be 
greater during the night (the active phase in mice), which does not necessarily model the 
human condition of disrupted sleep at night (the usual inactive phase for humans). 
However, the overall decrease in bout lengths in the 5XFAD mice suggests increased 
fragmentation and disruption in sleep consolidation throughout the day. This finding is 
likely to be relevant to human sleep disturbances, since mice (unlike humans) usually 
exhibit considerable amounts of sleep during both the day and night. Assessment of the 
sleep-wake parameters for the 6 h immediately after sleep deprivation (for 4 h) indicated 
that genotype did not affect bout length or sleep percentage in either males or females, 
although there was a general trend of reduced bout length in both sexes.  
            In general, our findings of decreased sleep bout lengths in 5XFAD mice support 
and extend previous findings of differences in sleep physiology in other AD mouse models. 
Reduced NREM duration has been reported in PLB1triple knock in mice (hAPP/hTau/hPS1), 
whereas lower REM sleep (during light period) was observed in PDAPP (overexpresses 
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hβAPP) and Tg2576 mice (Huitron-Resendiz, Sanchez-Alavez et al. 2002, Zhang, Veasey 
et al. 2005, Platt, Drever et al. 2011). APPswe/PS1δE9 mice aged 9 months had reduced 
REM and NREM sleep stages across both light and dark phases (Bertram, Rook et al. 2011, 
Roh, Huang et al. 2012). However, some AD mouse models, such as APP/PS1 knock-in 
mice, do not exhibit obvious changes in sleep (Bassett, Gogakos et al. 2012, Duncan, Smith 
et al. 2012, Jiang, Franklin et al. 2012).   
            In the current study, we did not find any change in the phase of the rhythm in 
5XFAD which replicates previous findings in APP/PS1 mice and other AD mouse models 
(Sterniczuk, Dyck et al. 2010, Bassett, Gogakos et al. 2012, Duncan, Smith et al. 2012, 
Jiang, Franklin et al. 2012). In this respect, the AD mice do not closely resemble the AD 
patients, which show large delays in the phase of their activity and temperature rhythms 
compared to those of normal elderly subjects. However, there were sex differences in the 
5XFAD transgenic mice. The mechanisms causing the sex differences in sleep over 24 
hours and sleep at night in the 5XFAD mice are unknown. It is possible that sex disparity 
in Aβ levels contributes to the sleep differences. Oakley et al in their studies on 5XFAD 
have reported that Aβ42 levels were higher in young females compared to age-matched 
males (until at least 9 months of age). This may explain the differences found between the 
two sexes in our study. Further, this observation indicates that the extent of sleep 
disruptions may be linked to the levels of Aβ as proposed by previous studies. In addition, 
some studies indicate that hormonal alterations in the later part of life in women may pose 
a higher risk of AD for them as compared to men, although some studies indicate otherwise 
(Morinaga, Ono et al. 2011, Barron and Pike 2012, O'Hagan, Wharton et al. 2012, Anaclet, 
Ferrari et al. 2014, Bhattacharya, Haertel et al. 2014, Civelek and Lusis 2014, Ju, Lucey et 
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al. 2014, Lan, Zhao et al. 2014, Lim, Ellison et al. 2014, Lim, Gerstner et al. 2014, Mang, 
Nicod et al. 2014, Niedowicz, Reeves et al. 2014, Webster, Bachstetter et al. 2014). It is 
possible that there may be other underlying causes present which require further 
investigation. In the 5XFAD mice, Devi et al illustrated that stressful conditions resulted 
in higher Aβ42 levels and plaque burden in hippocampus of females but not in males (Devi 
and Ohno 2010). Sex differences were also seen in a study of Tg2576 mice (Wisor, Edgar 
et al. 2005, Wisor and Kilduff 2005). Post AD pathology (22 months old), females in 
addition to exhibiting sleep-wake alterations common to males also showed increased 
REMS. However, Tg2576 mice (15-17 months) did not show any significant effect of sex 
or sex X genotype interaction on theta to delta ratio in the EEG (Wisor, Edgar et al. 2005, 
Wisor and Kilduff 2005). In another study in 3XTg mice, males with AD pathology did 
not show genotypic differences in circadian phase shifts post AD pathology but females 
had a tendency towards large circadian phase shifts in response to light pulses presented in 
the early subjective night (Sterniczuk, Dyck et al. 2010).   
            While the present findings indicate that the 5XFAD mice exhibits some sleep 
alterations that are relevant to AD, there were also some limitations to this study. One 
limitation was that the algorithms currently used by the piezoelectric system do not 
distinguish REM sleep from NREM sleep, although algorithms under development may be 
able to do this in the future. Also, it should be kept in mind that this mouse model represents 
the advanced stage of AD with its early onset and extensive pathology.  
            5XFAD mice show amyloid pathology- an important characteristic of Alzheimer’s 
disease - but fail to exhibit hyperphosphorylated tau. Those AD mouse models that do show 
tau pathology differ from human clinical presentation in important AD features like 
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neuronal loss and intraneuronal Aβ (Wirths and Bayer 2010, Barone and Menna-Barreto 
2011, Bertram, Rook et al. 2011, Bliwise, Mercaldo et al. 2011, Bruce-Keller, Gupta et al. 
2011, Brunner, Gotter et al. 2011, Holtzman, Morris et al. 2011, Jiang, Striz et al. 2011, 
Keane, Goodstadt et al. 2011, Li, Cheung et al. 2011, Lloyd 2011, Moreno-De-Luca, 
Helmers et al. 2011, Morinaga, Ono et al. 2011, Pack and Pien 2011, Pavlova and Sheikh 
2011, Philip, Sokoloff et al. 2011, Platt, Drever et al. 2011, Raizen and Wu 2011, Rillich, 
Schildberger et al. 2011, Ringwald, Iyer et al. 2011, Rolls, Colas et al. 2011, Skarnes, 
Rosen et al. 2011, Sperling, Aisen et al. 2011, Barron and Pike 2012, Bertram and Rook 
2012, Callander, Bolton et al. 2012, Jawhar, Trawicka et al. 2012, Sakurai 2012, Zeng, 
Mott et al. 2012, Dyakonova and Krushinsky 2013, Fitzsimmons and Bertram 2013, 
Reichert and Gerhardt 2013, Stevenson and Schildberger 2013).  In spite of their various 
limitations, the 5XFAD mice and other AD mouse models exhibit sleep alterations that 
resemble some aspects of the sleep disruptions reported in AD patients. As described 
above, the 5XFAD mouse model is especially useful because it exhibits neuronal loss, 
similar to AD patients, and the early onset pathology in the 5XFAD mice allows them to 
be studied at younger ages than other AD mouse models.  Therefore, this mouse model is 
useful for investigations of the role of sleep loss in the progression of AD. 
            Recent studies show that sleep impacts Aβ levels in the brain. Diurnal oscillations 
of Aβ levels in human cerebrospinal fluid (CSF) and in mouse hippocampal interstitial 
fluid (ISF) exhibit lowest values during the rest phase. Furthermore, sleep deprivation 
during the normal rest phase elevates these Aβ levels (Kang, Lim et al. 2009). The diurnal 
rhythms of Aβ levels become attenuated and eventually lost as Aβ deposition in the brain 
progresses (Bertram, Rook et al. 2011, Roh, Huang et al. 2012). These changes begin in 
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parallel to onset of sleep disruptions in mice (Bertram, Rook et al. 2011, Roh, Huang et al. 
2012). Further, a recent study by Xie and colleagues demonstrated that sleep strongly 
increases clearance of Aβ, one of the metabolites generated by neuronal activity, which is 
greatest during wakefulness (Xie, Kang et al. 2013). These studies further support the 
concept that sleep disruption may be one of the causal factors involved in progression of 
the AD. A feedback loop might exist where Aβ accumulation might deteriorate sleep 
quality which could lead to further Aβ accumulation and increasing the susceptibility of 
the patients further to the pathophysiological changes associated with AD. 
Conclusions 
            The 5XFAD mouse model of AD overexpresses amyloid β at an early stage and is 
therefore useful in studying the effect of Aβ on sleep. Our findings showed various sleep-
wake alterations in both male and female 5XFAD mice under baseline conditions and also 
after sleep deprivation. The overall decrease in bout length suggests increased 
fragmentation and disruption in sleep consolidation that may be relevant to human sleep 
disturbances in AD and other neurological diseases. Because sleep disturbances precede 
overt AD symptoms by ten years or more, and experimental sleep disruption accelerates 
Aβ deposition, sleep enhancement may be a valuable therapeutic target for treatment of 
AD that can be investigated in 5XFAD mice.   
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Abstract  
 
Sleep has been suggested to play a variety of roles ranging from learning, memory 
consolidation, and clearance of toxic metabolites such as amyloid beta (A), to regulation 
of energy metabolism. Current data suggest bidirectional roles for sleep and Alzheimer’s 
Disease (AD), with poor sleep promoting AD, and AD increasing sleep disruption. 
Insufficient sleep is also correlated with an increased risk of obesity and type 2 diabetes 
mellitus (T2DM), which in turn are increasingly linked to AD. Previous studies have shown 
that leptin-resistant db/db mice, which have T2DM and obesity, have attenuated sleep-
wake rhythms in addition to increased sleep duration and sleep fragmentation. AD mouse 
models often show fragmented and/or reduced sleep. To examine the interaction of T2DM 
and AD, a novel mouse model was created by combining the db/db mutations with a 
commonly used mouse model of AD (APP/PS1). Mice with these combined mutations 
display severe cerebrovascular pathology, without increased A deposition (Neidowicz et 
al., 2014). Cognitive impairments in the db/AD mice were more profound than those in 
db/db or APP/PS1 mice (Neidowicz et al., 2014). Given the association of sleep disruptions 
in both of these disorders, we examined multiple sleep variables in db/AD, and the 
individual mouse models db/db and APP/PS1. In the db/AD mice, we found significant 
alterations in baseline sleep including age associated reduced sleep duration across 24h, 
and in the dark as well as the light phase. The most significant differences were found 
during the dark phase. We also found sex and age effects for many of the sleep parameters. 
These db/AD mice may serve as an important tool to study the mechanisms involved at the 
intersection of T2DM and AD, and to examine sleep interventions to slow the progression 
of disease. 
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Introduction 
 
 Sleep is indispensable for the role it plays in learning, memory consolidation, 
energy conservation, and the overall health of an animal. Sleep is also important for optimal 
cognition over short time periods, and probably also over longer time periods of many 
years (Ellenbogen 2005, Killgore and Weber 2014). Sleep perturbations are seen in a wide 
array of diseases- neuromuscular disorders, neurodegenerative diseases including 
Alzheimer’s disease (AD), Parkinson’s disease, and Diffuse Lewy Body disease, as well 
as metabolic disorders such as obesity and type 2 diabetes mellitus (T2DM) (Knutson, 
Spiegel et al. 2007, Rothman and Mattson 2012, Suzuki, Miyamoto et al. 2012). With the 
increased life expectancy of the human population, the prevalence of age-related ailments 
such as AD and T2DM have reached epidemic proportions; therefore, it is imperative to 
interrogate the underlying mechanisms by which sleep modulates these pathologies.  
 
AD is one of the most common types of dementia; characterized by amyloid beta 
(A) plaques and neurofibrillary tangles as the hallmarks (Barker, Luis et al. 2002). 
Approximately, 25-60% of AD patients are affected by profound circadian and sleep-wake 
aberrations which are the major reason for their institutionalization (Pollak, Perlick et al. 
1990, Bianchetti, Scuratti et al. 1995, Moran, Lynch et al. 2005, Guarnieri, Adorni et al. 
2012). Circadian dysfunction is presented as a reduction of locomotor activity, and a phase 
delay of as much as 4 hours in body temperature and activity rhythms (Satlin, Volicer et 
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al. 1995, Harper, Stopa et al. 2001, Harper, Volicer et al. 2005). The sleep alterations are 
manifested as a reduction in slow wave sleep (Loewenstein, Weingartner et al. 1982, 
Martin, Loewenstein et al. 1986, Vitiello, Prinz et al. 1990) and rapid eye movement 
(REM) sleep, increased latency to REM sleep, increased sleep fragmentation associated 
with reduced nighttime and increased daytime sleepiness (Holth, Patel et al. , Prinz, 
Peskind et al. 1982, Martin, Loewenstein et al. 1986, Vitiello, Prinz et al. 1990, Petit, 
Gagnon et al. 2004). These sleep impairments in turn are positively correlated to the degree 
of progression of AD and also believed to lead to memory deficits (Walker 2009). 
Aggregation of A in the brain has been implicated in sleep perturbations and also 
in AD pathogenesis. A deposition has been reported to begin as early as 10-15 years 
before the onset of clinical symptoms, and sleep disruptions as well can be seen since 
preclinical stages of AD (Kang, Lim et al. 2009, Potvin, Lorrain et al. 2012, Sterniczuk, 
Theou et al. 2013, Hahn, Wang et al. 2014). In one study, cognitively normal individuals 
with increased A deposition were found to have shorter sleep and poorer quality of sleep 
(Ju, McLeland et al. 2013, Malkki 2013, Spira, Gamaldo et al. 2013). Studies in animal 
models also corroborate these findings and demonstrate an association between sleep 
perturbations and AD pathogenesis. In the APPswe/PS1dE9 AD mouse model, normal 24-
hour fluctuations of A in the hippocampal interstitial fluid (ISF) dissipated in older 
animals with A plaque deposition along with disruption of sleep-wake cycle (Roh, Huang 
et al. 2012). Recently, Xie and colleagues have shown that sleep is linked to as much as 
60% increase in brain interstitial space, which in turn facilitates increased A clearance 
(Xie, Kang et al. 2013). Thus, the existing data posits that there exists a bidirectional role 
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for sleep and AD, with poor sleep increasing A deposition and reducing clearance, and 
increasing A leading to more sleep disruption. 
T2DM, a chronic metabolic disorder, is a major health concern that affects 8% of 
adults in America (Harris, Flegal et al. 1998). T2DM and associated obesity, in turn are 
risk factors for other diseases including cardiovascular diseases as well as metabolic 
syndrome (Kahn, Buse et al. 2005). Similar to bidirectional relationship between A 
deposition and AD, it has been postulated that a feedback loop exists between sleep 
impairments and type 2 diabetes (Barone and Menna-Barreto 2011). Additionally, reduced 
sleep is another risk factor for diabetes (Laposky, Bradley et al. 2008). Multiple studies 
have shown that sleep restriction (or deprivation) leads to reduced insulin sensitivity and 
impaired glucose metabolism (Knutson, Spiegel et al. 2007, Donga and Romijn 2014). 
Conversely, in rodents, diet (type, its availability and timings) has been shown to affect 
sleep patterns (Mavanji, Billington et al. 2012). The db/db mice have attenuated sleep-
wake rhythms in addition to increased sleep fragmentation and increased overall sleep 
duration, which further strengthens the idea that sleep and metabolism are linked inversely 
(Laposky, Shelton et al. 2006, Laposky, Bradley et al. 2008).  
AD and T2DM, which are both age-associated diseases, share several similarities 
such as cognitive deficits (Stolk, Breteler et al. 1997, Saedi, Gheini et al. 2016, Zilliox, 
Chadrasekaran et al. 2016), degenerative changes, and sleep alterations (Kuusisto, Koivisto 
et al. 1997, Luchsinger, Tang et al. 2004, Peila, Rodriguez et al. 2004, Yaffe, Blackwell et 
al. 2004, Ronnemaa, Zethelius et al. 2008, Ronnemaa, Zethelius et al. 2009, Schrijvers, 
Witteman et al. 2010). Amyloid is conceived to be a main factor responsible for the 
observed cellular degeneration of brain and pancreas in AD and T2DM, respectively 
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(Abedini and Schmidt 2013). Since the first Rotterdam study, many other studies have 
shown that individuals with diabetes have a doubled risk of AD (Ott, Stolk et al. 1999, 
Kroner 2009). Janson et al in a study of Mayo Clinic Alzheimer Disease Patient Registry 
(ADPR) found that diabetic patients are more vulnerable to AD compared to non-diabetic 
individuals (Janson, Laedtke et al. 2004). Thus, it is proposed that there may be common 
pathophysiological mechanisms related to both the diseases. 
The patients with AD and a prior history of T2DM have cerebrovascular anomalies, 
in addition to the typical AD-related neuropathology without showing additional A 
burden. The role of cerebrovascular anomalies or vascular dementia, a frequent 
comorbidity with Alzheimer’s disease, is poorly understood. An animal model 
recapitulating both disease aspects is critical to understand how the two conditions interact 
at the cellular and molecular level, and promote cerebrovascular abnormalities. Previous 
attempts to model key features of both- diabetes and AD in rodents includes utilization of 
streptozotocin, which induces type 1 rather than type 2 diabetes (Park 2011, Thibault, 
Anderson et al. 2013). Other approaches such as feeding of a high-fat or western diet had 
only short term effects, while combined models of APP and insulin-resistant, or APP and 
leptin-resistant mice showed only a limited spectrum of pathology (Killick, Scales et al. 
2009, Studzinski, Li et al. 2009, Julien, Tremblay et al. 2010, Kohjima, Sun et al. 2010, 
Takeda, Sato et al. 2010).  
Recently, Niedowicz and colleagues created a novel mouse model by crossing 
leptin resistant db/db mice with APP/PS1, a knock-in mouse model of AD (Neidowicz et 
al., 2014). The parental strains- db/db animals are obese since the age of 3-4 weeks, display 
elevated plasma insulin at an early age of 10 days and increase in blood sugar levels since 
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4 to 8 weeks. They have a shorter life span and tend to live upto 18-20 months of age 
(Coleman 1978). A deposition in APP/PS1 animals can be observed since the age of 6 
months (Anantharaman, Tangpong et al. 2006). Neuritic plaques do not appear until 9 
months of age (Murphy, Beckett et al. 2007). Cognitive and memory deficits have been 
reported during old- age (Bruce-Keller, Gupta et al. 2011). 
The db/AD mice resulting from the cross of the above 2 strains, displayed 
additional pathologies than either of the parental lines, in particular, severe cerebrovascular 
abnormalities including aneurysms and small strokes, without increased A deposition 
(Neidowicz et al., 2014). Cognitive impairment on the Morris water maze task was 
markedly profound in these mice compared to db/db and APP/PS1 mice alone. These 
db/AD mice are obese and glucose intolerant beginning at an early age and have 
parenchymal amyloid plaques similar to parental lines (Neidowicz et al., 2014). Thus, the 
db/AD mouse model mimics several of the significant features of humans with T2DM and 
AD. Given the role of sleep in both of these disorders, in this study we aimed to evaluate 
multiple sleep variables in the combined mouse model (db/AD) and also, the individual 
mouse models db/db and APP-PS1 and WT mice for comparisons. 
Methods and Design  
Generation of combined- db/AD mice 
 As  described previously, the db/AD mice were generated by crossing APPNL/NL 
/PS1 P264L/P264L
  
(APP/PS1) knock-in mice (Citron, Oltersdorf et al. 1992, Mullan, Crawford 
et al. 1992) with leptin receptor-deficient mice (Leprdb/db) (Niedowicz, Reeves et al. 2014). 
Briefly, the original heterozygous Lepr+/db stock (homozygous db/db animals are infertile) 
on a C57BL/6J background was purchased from The Jackson Laboratories, and APP/PS1 
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mice on CD-1/129 background were obtained from a breeding colony maintained at 
University of Kentucky and derived from stock purchased from Cephalon. F1 mice, 
heterozygous for the 3 alleles were then crossed to generate offspring of the genotypes: 
wild type, and homozygous db mice that were in turn wild type and homozygous for APP 
and PS1. For our study, we utilized the genotypes as listed: Leprdb/db  X APPNL/ NL /PS1 
P264L/P264L (db/AD), Lepr+/+  X APPNL/ NL /PS1 P264L/P264L
  
(AD), Leprdb/db  X APP+/+ /PS1 
+/+ (db) and Lepr+/+  X APP+/+ /PS1 +/+ (WT).  
Experimental procedures 
Animal housing and sleep phenotyping  
This study utilized individually housed control and mutant mice generated on B6 
X CD1/129 background. We included both males and females that were 2 to 16 months 
old. The animals were provided with ad-libitum access to water and food. Prior to the sleep 
recordings, mice were group-housed and exposed to a 14:10 alternating light/dark (LD) 
cycle (lights on at 8 h). We recorded a total of 119 animals in several subgroups as listed 
in Table 1. The animals underwent sleep recording in 2 batches based on their availability 
at two different times. The first batch included 29 animals, and the rest of the animals were 
recorded in the second batch. The baseline sleep data were collected for 3 days from most 
animals but for only 2 days in 30 animals because of issues at the animal facility. During 
sleep recording, the mice were exposed to a 12:12 LD cycle (lights on at 4am for first batch 
and 8am for second batch). The PiezoSleep system used in the study is comprised of 8 quad 
cage units, which allowed assessment of up to 32 mice per experiment. Pine shavings were 
added as bedding to the cages, and cotton squares (nestlets), which could be shredded and 
used to build nests, were provided as environmental enrichment. All experimental 
53 
 
procedures were approved by the Institutional Animal Care and Use Committee at the 
University of Kentucky and are consistent with the Institute of Laboratory Animal 
Resources Guide for Care and Use of Laboratory Animals, 8th edition.  
Genotyping 
Tail snips were collected before weaning for genotyping for APP, db and PS1. 
Genomic DNA was isolated and purified using the Promega Wizard Genomic DNA kit 
(Promega; Madison, WI). db genotyping was then carried out using a single nucleotide 
polymorphism Taqman genotyping kit purchased from Applied Biosystems Life 
Technologies. As for APP and PS1, genotyping was performed using Promega GoTaq 
Flexi DNA Polymerase (as described previously; (Anantharaman, Tangpong et al. 2006)). 
Sleep recording with piezoelectric system 
Sleep and wake states were determined using the PiezoSleep System as described 
elsewhere (Flores, Flores et al. 2007, Donohue, Medonza et al. 2008, Mang, Nicod et al. 
2014). The system is comprised of plexiglass cages lined with piezoelectric films across 
the cage floor that detect pressure variations. For all sleeping postures, pressure variations 
from breathing are detected. Sleep states are characterized by quasi-periodic signals with 
low variations in amplitude, whereas wakefulness and rest states are characterized by 
irregular transient and high amplitude pressure variations corresponding to voluntary body 
movements and weight shifting.  
Signal features sensitive to the differences between the sleep and wake states are 
extracted from 8-second pressure signal segments, and classification is automatically 
performed every 2 seconds using overlapping windows. Sleep-wake decisions in the 2-
second intervals are binned over specified time periods (e.g., 5 minutes, 1 hour) for local 
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percent sleep/wake statistics. In addition, durations of consecutive sleep states are used to 
compute mean sleep bout lengths. For the current study, the PiezoSleep system eliminates 
commonly occurring short arousals (as seen during instances of stirring or twitching) 
during sleep bouts. These arousals were counted as wake instances in the previous chapter, 
resulting in shorter bout lengths. 
The sleep bout is calculated as the amount of time from initial sleep state to the first 
30-second interval when the mouse is awake for over 50% of the time. The sleep bout 
length computed with the 50% wake in the 30-second interval rule typically marks a clear 
transition into an extended wake period, where the mouse does not quickly transition back 
into the sleep state. The piezo system has been validated with simultaneous EEG/EMG and 
human scoring of mice demonstrating a classification accuracy of over 90% in mice 
(Donohue, Medonza et al. 2008, Mang, Nicod et al. 2014). Mice unlike humans, are 
nocturnal and polyphasic i.e. they have fragmented sleep (each episode termed as bout), 
distributed across 24 h, and more so during daytime. Thus their sleep is measured in terms 
of number and length of such sleep bouts. The sleep statistics analyzed under baseline 
(undisturbed) conditions for experiments in this report were: percent sleep over 24 h 
periods, percent sleep during light phase, percent sleep during dark phase, average sleep 
bout length (across 24 h, light phase, and dark phase periods).  
Statistical Analysis 
Females and males were broadly grouped into 2 age groups: young (2-8 months), 
and old (8.5-15 months), given the predicted life span of db/AD mice is 15-16 months 
(Niedowicz, Reeves et al. 2014). For baseline data, we conducted ANOVA (analysis of 
variance) to determine statistically significant differences for the sleep-wake parameters 
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between different genotypes; segregated into subgroups by sex and age. As mentioned 
earlier, the animals were recorded in 2 batches. Initial assessment showed that there was 
no difference between first and second batch of animals therefore, the data was merged for 
subsequent analysis.  
To examine the association between sleep parameters and interaction effects 
(genotype X sex, genotype X age, age X sex), baseline data was examined using multiple 
regression model. Each of the six sleep-wake parameters was treated as the outcome of 
interest. Genotype (db/AD, AD, db, WT), sex (male and female) and age (young and old) 
were included as categorical predictors. Backward selection approach was utilized with a 
significance level of five percent for the models, starting with the main effects of all 3 
covariates and all the possible 3 two-way interactions (described above). Individual 
predictor terms and their interaction terms were removed if the P value was less than 0.05. 
JMP statistics software version 12.0 was used for all modeling analysis and ANOVA. Plots 
were used to test the data for normal distribution and homogeneity of variance. 
Results 
In all, 119 animals- males and females, categorized as young and old were utilized. 
The number of animals per sub-group is listed in table 1. The means and standard error for 
each group is presented in table 2.  
Females 
Genotypic differences 
Total sleep time (% sleep per 24h) was increased in old db females compared to 
age-matched all other 3 genotypes- db/AD (p<0.0011), wild type (p=0.019) and AD 
(p=0.0224). A similar genotype effect was seen concerning sleep during the dark phase, in 
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that db mice had increased sleep amounts compared to the other 3 groups of animals- 
db/AD (p=0.0017), AD (p=0.001) and WT (p=0.0017). The order follows: db>WT and 
AD>db/AD for sleep across 24h and dark phase. This indicates that genotypic differences 
in sleep duration mainly occur during the active or dark phase. The genotypic effect was 
less prominent in younger animals; db/AD had elevated sleep compared to controls across 
24 h (p=0.0291) as well as during the dark phase (p=0.0041). db/AD and db had 
comparable sleep durations. There was no genotype difference in bout length durations for 
any of age groups (Figure 1 and Table 2).   
Effect of age 
Old db/AD mice slept less than the young animals across both light and dark phase. 
In contrast, bout length did not reflect an age difference. We did not have any females in 
the AD young group. For the remaining groups, we did not find any effect of age. 
Males 
Genotypic differences 
  Younger males displayed more prominent genotypic differences unlike females 
which showed marked differences in older age. Both db and db/AD mice have increased 
duration of sleep across 24 h, and dark phase compared to WT and AD animals. The total 
sleep duration is comparable between db mice and db/AD mice, and between WT mice and 
AD mice. Concerning sleep duration during the light phase, db/AD and db mice mice had 
similar sleep durations that were elevated compared to WT (p=0.0151 and 0.0129 
respectively). Sleep durations tend to be equal for db/AD and db across light phase. Bout 
length across 24h was in the same mean range for all the groups. Mice of the db/AD 
genotype had shorter sleep bouts than WT mice during the dark phase, and AD mice had 
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increased bout lengths with respect to db animals for the light phase. AD mice did not differ 
from WT for bout lengths across 24 hours or during the dark or light phase. Concerning 
the older subjects, no db mice were available. For the other three groups, there were no 
differences in sleep amounts or the bout lengths. 
Effect of age 
The older males of the db/AD genotype slept less during the light phase than 
younger mice. Like db/AD females, younger male littermates slept longer than old animals 
during light phase. AD young males had less sleep duration compared to old mice during 
24h and dark phase. Control males in general had increased bout lengths during night 
compared to females. db/AD young males during light phase displayed increased bout 
lengths than females of same age.  
Multiple regression 
 The adjusted multiple regression models are shown in Table 3, with each sleep 
parameter as an outcome of interest, and genotype, age, sex or/and the interaction terms- 
ageX genotype and sex X genotype as predictor variables. The co-variates included in each 
of the model is depicted in the Table 3. The selection of the variables is based on backward 
elimination as described in the Methods section. For sleep across 24h, the Radjusted
2 is 0.19 
which means that the model explains 19% of variation seen in overall sleep. The diabetic 
animal group has significantly higher sleep percent (p=0.0007) than the control group after 
controlling for age and ageXgenotype interaction effect. Age and genotype interaction 
effect was significant for db/AD group compared to WT animals. For sleep across dark 
phase, the model explained 26% of the variation. After adjusting for other covariates in the 
model, diabetic animals were estimated to sleep 10% more during the dark phase compared 
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to controls (p<0.0001). In addition, AD animals slept approx. 6% less than the reference  
(control) group (p=0.0045). Similar to total sleep, age and genotypic interaction for db/AD 
animals were associated with sleep across the dark phase (p=0.0002) as well as across the 
light phase (p=0.0034).  
Sex was included as covariate in the models for bout length. In case of bout length 
across 24h, AD animals had increased bout length (42 s/bout, p=0.0236) after controlling 
for other covariates in the model. Females compared to males had shorter sleep bout across 
24 h (31.5 s; p=0.0055) as well as during the dark phase (28.63 s; p=0.0077). Additionally, 
sex Xage interactions were significant for the old animals (p=0.0159) for bout length 
during the dark phase. Older animals had shorter bout length during light phase (39.32s; 
p=0.0359) than the younger mice after adjusting for the other predictors in the model. 
Females also have reduced bout lengths for the light phase (39.48 s; p=0.013). AD animals 
have increase in light phase bout lengths by an estimated mean of 100s (p=0.0004) with 
respect to the controls.  
 
 
 
 
 
 
 
 
 
59 
 
Table 3 List of the sample size for each of the group divided based on genotype, sex and 
age 
Animal count 
Genotype-sex-age Count 
Db/AD -F-old 7 
Db/AD -F-Young 17 
Db/AD -M-old 4 
Db/AD-M-Young 8 
Db-F-old 3 
Db -F-Young 8 
Db -M-Young 11 
AD -F-old 19 
AD -M-old 7 
AD -M-Young 3 
WT -F-old 14 
WT -F-Young 6 
WT -M-old 7 
WT -M-Young 4 
Total 119 
 
Table 4 . Effect of genotype on sleep wake traits under baseline conditions for males and 
females 
Males   Genotype   
Parameter Age group WT  DB AD AD/Db 
% Sleep 24 h Old 47.6±2.3 N.D. 50.7±1.6 43.8±7.5 
 Young 43.5±2.2 55.6±1.6 44.3±3 53.7±1.3 
% Sleep Dark Old 38.7±3 N.D. 37.2±2.5 35.8±3.8 
 Young 31.4±2.5 45.3±1.8 25.3±3.7 41.3±2.5 
% Sleep Light Old 56.5±2.3 N.D. 64.2±2 51.9±11.4 
 Young 55.7±3.5 65.9±2.4 63.3±2.4 66.1±1.5 
Bout length 24h Old 439.6±44.6 N.D. 528.2±41.1 465.2±119.7 
 Young 501.2±52.3 466.7±27.1 542.2±31.8 462.7±21.5 
Bout length Dark Old 384.6±43.4 N.D. 429.9±42.6 412.1±97.3 
 Young 438.4±57.2 372.8±23.1 313.4±41.2 330.2±27 
Bout length Light Old 496.7±53.4 N.D. 633.9±44 512±142.4 
 Young 562.3±51.1 577.6±36.1 763.4±14.5 660.7±57.7 
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Females   Genotype   
Parameter Age group WT  DB AD AD/Db 
% Sleep 24 h Old 48.7±1.8 58.2±2.1 49.2±0.8 43.3±3.9 
 Young 40.9±8.2 51.9±4 N.D. 53.5±1.7 
% Sleep Dark Old 33.9±2.9 52.9±2.1 33.4±1.5 32.4±4.2 
 Young 26.4±6.2 42.7±4.4 N.D. 43.6±2.4 
% Sleep Light Old 63.5±1.9 63.6±2.4 65±1.4 54.3±4.4 
 Young 55.4±11.3 61.1±3.8 N.D. 63.5±1.6 
Bout length 24h (s) Old 395±29.3 324.5±15.1 443.5±29 404.8±66.7 
 Young 385.8±59.3 438.7±34.5 N.D. 419.6±24.7 
Bout length Dark (s) Old 272.6±16.8 275.6±22.3 324.4±21.6 310.3±72.5 
 Young 280.3±29.5 369.1±34.5 N.D. 360.3±31.4 
Bout length Light (s) Old 476.5±34.1 386.1±4.6 571.1±52.8 485.9±65.8 
 Young 445.9±104.8 511.7±38.1 N.D. 494.2±24.2 
  
Values represent mean ± SEM. N.D. No data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
     
 
     
 
     
 
Figure 4 Sleep–wake patterns in AD, db, db/AD and WT littermates under baseline conditions. 
Average percent sleep analyzed over (A) 24 h, (B) dark phase, and (C) light phase. (D–F) depicts 
average bout length in seconds (s) over (D) 24 h (E) dark phase, and (F) light phase. 
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Table 5 Multiple linear regression results using sleep parameters as the outcome of interest. 
Estimate corresponds to the respective non-intercept parameter estimates in the final 
model. 
 
Predictor Estimate Standard 
error 
P value 
1. Sleep % across 24 
hours 
 Radj2=0.19 p<0.0001 
Age:                           
Young 
 
Reference 
  
Old 0.62 0.96 0.5187 
Genotype:                   
WT 
 
Reference 
  
db/AD -0.76 1.38 0.5840 
db 6.83 1.97 0.0007 
AD -1.91 1.77 0.28 
AgeXGenotype:     
AgeXWT 
 
Reference 
  
AgeXdb/AD -5.66 1.38 <.0001 
AgeXdb 1.49 1.97 0.45 
AgeXAD 1.59 1.77 0.37 
2. Sleep % across dark 
phase 
 Radj2=0.26 p<0.0001 
Age:                  
Young 
 
Reference 
  
Old 1.49 1.10 0.1791 
Genotype:                  
WT 
Reference   
db/AD 0.63 1.59 0.6921 
db 10.92 2.26 <.0001 
AD -5.89 2.03 0.0045 
AgeXGenotype:     
AgeXWT 
 
Reference 
  
AgeXdb/AD -6.11 1.59 0.0002 
AgeXdb 2.83 2.26 0.2136 
AgeXAD 1.20 2.03 0.5549 
3. Sleep % across light 
phase 
 Radj2=0.08 p=0.0225 
Age:                          
Young 
 
Reference 
  
Old -0.25 1.20 0.8371 
Genotype:                    
WT 
 
Reference 
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db/AD -2.15 1.74 0.2185 
db 2.75 2.47 0.2688 
AD 2.06 2.22 0.3543 
AgeXGenotype:     
AgeXWT 
 
Reference 
  
AgeXdb/AD -5.20 1.74 0.0034 
AgeXdb 0.15 2.47 0.9514 
AgeXAD 1.99 2.22 0.3726 
 
Predictor Estimate Standard 
error 
P value 
1. Bout length 24h Radj2=0.07 p=0.0135 
Genotype:                          
WT 
 
Reference 
  
db/AD -7.37 17.51 0.6746 
db -12.10 20.79 0.5617 
AD 42.56 18.55 0.0236 
Sex:  
Male 
 
Reference 
  
Female -31.50 11.14 0.0055 
2. Bout length Dark Phase Radj2=0.08 p=0.0162 
Age: 
Young 
 
Reference 
  
Old -2.77 12.49 0.82 
Genotype: 
WT 
 
Reference 
  
db/AD -3.99 17.29 0.8178 
db 5.62 21.41 0.7934 
AD 21.80 19.54 0.2668 
Sex: 
Male 
 
Reference 
  
Female -28.63 10.55 0.0077 
SexXAge: 
SexXYoung 
 
Reference 
  
SexXOld -26.25 10.72 0.0159 
3.Bout length Light phase Radj2=0.13 P=0.0012 
Age: 
Young 
Reference   
Old -39.32 18.51 0.0359 
Genotype: 
WT 
 
Reference 
  
db/AD -14.93 25.63 0.5615 
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db -52.83 31.74 0.0988 
AD 106.01 28.96 0.0004 
Sex: 
Male 
 
Reference 
  
Female -39.48 15.64 0.013 
SexXAge: 
SexXYoung 
 
Reference 
  
SexXOld 16.89 15.89 0.29 
 
The percentage of total variation in any of the sleep parameter that can be explained by our 
model is indicated by value of Radj2 as listed in the table. 
 
Discussion 
Sleep is a multifaceted process with diverse indirect and/or direct functions in 
cognition, metabolism, learning and memory consolidation, and amyloid beta clearance 
(Tucker, Hirota et al. 2006, Knutson, Spiegel et al. 2007, Marshall and Born 2007, 
Diekelmann and Born 2010, Xie, Kang et al. 2013, Krueger, Frank et al. 2016). 
Dysfunctional sleep therefore has detrimental effects on health, and is linked to many 
pathological conditions including AD and T2DM (Grandner, Seixas et al. 2016). 
Previously, sleep aberrations were considered to be a byproduct of these pathologies but 
mounting evidence supports the proposition that a reciprocal relationship exists between 
sleep loss and AD, and sleep apnea and T2DM.  
 Apart from cognitive decline, T2DM can also lead to renal impairments, vision 
loss and cardiovascular disease (Association). It also increases the risk of dementia, 
specifically vascular dementia and AD (Ott, Stolk et al. 1999, Xu, Qiu et al. 2004, Biessels, 
Staekenborg et al. 2006, Luchsinger, Reitz et al. 2007, Reijmer, van den Berg et al. 2010, 
Vagelatos and Eslick 2013). Furthermore, in individuals with T2DM  who also exhibit 
dementia, there is an increased incidence of cerebrovascular pathology (Ahtiluoto, 
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Polvikoski et al. 2010). In addition to the pathways regulating interaction of AD and 
T2DM, the cerebrovascular dysfunction co-occurring with other dementias or in isolation 
is poorly understood (Grinberg and Heinsen 2010). A mouse model was thus generated by 
crossing a db/db mouse with APP/PS1- a knock-in AD animal model. This novel db/AD 
mouse model can further our understanding of diabetes promoting neurodegenerative 
diseases, specifically AD and vascular dementia, and other secondary implications 
resulting from interaction between AD and db. The db/AD mouse recapitulates the key 
aspects of both AD and db parental lines. These mice are obese, insulin resistant and 
glucose intolerant, and have amyloid deposition similar to their parental lines. In addition, 
they also exhibit exacerbated cerebrovascular abnormalities such as aneurysms and 
strokes, without any additional burden of amyloid beta similar to the human disease 
condition. They have a significant decline in cognition- more than either of the AD or db 
parents, which might be due to the vascular abnormalities. In our current studies, we were 
interested in evaluating the effect of db/AD genotype on sleep phenotypes. We assessed 
several sleep-wake parameters in db/AD animals as well as their parental lines to 
understand holistically the effect of the interaction between db and AD on sleep, and the 
origin of these sleep differences. In addition to the main effect of genotypes, we also 
examined 2-way interaction amongst genotype, sex and age. 
Multiple regression indicated that bout length is affected by sex and females tend 
to have shorter bouts compared to males. Shorter sleep duration during the dark phase was 
found in case of AD animals, after controlling for other variables. Increased bout lengths 
were found across 24h as well as light phase. In a previous study conducted on the parental 
APP/PS1 strain, our research group did not find any effect of genotype on sleep for the 
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male mice. In that study, there was an effect of age on percent sleep during day and bout 
length during either day or night, with older animals sleeping less and having shorter bouts 
of sleep (Duncan, Smith et al. 2012).  In the current study, one-way ANOVA indicated that 
aging increases sleep in male AD mice, in contrast to the earlier study. This difference 
might be related to several factors, including differences in the age ranges, low sample size 
for younger group, or a genetic difference in the background strain (i.e., additional BL6 
composition of the mice in the current study).  Our findings are similar to the ones reported 
in 5XFAD AD mouse model.  5XFAD male and female mice, with early onset of AD 
pathology, exhibited increased sleep fragmentation (as indicated by longer sleep bouts) 
with prominent effects evident during the dark phase than light phase (Sethi, Joshi et al. 
2015). In addition, females also had reduced overall sleep due to marked reduction in sleep 
in dark phase. Other AD models such as PLB1triple  (hAPP/hTau/hPS1) and TgCRND8 mice 
were found to have reduced NREM sleep. In contrast, PDAPP (overexpresses hBAPP) and 
Tg2576 have less REM sleep during dark phase (Huitron-Resendiz, Sanchez-Alavez et al. 
2002, Zhang, Veasey et al. 2005, Platt, Drever et al. 2011, Colby-Milley, Cavanagh et al. 
2015). Another, related mouse- APP/PS1 with a different PS1 mutation 
(APPswe/PS1dE9), was reported to have reduced REM and NREM sleep (Roh, Huang et 
al. 2012).  
Sleep and metabolism are mutually exclusive processes (Adamantidis and de Lecea 
2008), with inadequate sleep resulting in reduced leptin and elevated ghrelin levels, in 
addition to an increase in BMI in a dose dependent way (Gupta, Mueller et al. 2002, Sekine, 
Yamagami et al. 2002, Taheri, Lin et al. 2004). In contrast, food deprivation in rats was 
linked to reduction in sleep duration, and refeeding to increase in its duration (Borbely 
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1977, Danguir and Nicolaidis 1979, Shemyakin and Kapas 2001, Minet-Ringuet, Le Ruyet 
et al. 2004). Sleep architecture is also modulated by the type of diet and the time of 
availability. As observed in mice, a high fat diet resulted in increased duration of NREM 
sleep, as well as number of episodes (Jenkins, Omori et al. 2006). The leptin deficient ob/ob 
mice and leptin insensitive db/db mice have altered sleep architecture reflected as 
fragmented sleep, and increased total NREM sleep. Furthermore, their sleep-wake rhythms 
are diminished, and NREM delta power and locomotor activity is reduced as well 
(Laposky, Shelton et al. 2006, Laposky, Bradley et al. 2008). Additionally, recovery sleep 
followed by sleep deprivation is also reduced in both db/db and ob/ob mice (Laposky, 
Shelton et al. 2006, Laposky, Bradley et al. 2008, Mavanji, Billington et al. 2012). Similar 
alterations in sleep-wake patterns have been reported in several other rodent models of 
obesity including obese zucker and spontaneously hypertensive rats, and diet-induced 
obese mice. Our results also depict similar sleep patterns for both db and db/AD animals 
for both the sexes. Marked differences were seen in particular during the dark phase where 
both db and db/AD animals slept longer than controls implicating the effect of db gene. 
Multiple regression reflected that age interacts with db/AD genotype for the sleep duration 
variables. Although we did not find any evidence of sleep fragmentation in these db/AD 
and db mice, increased sleep during the active phase of the mouse emulates the human 
condition. We found similar sleep phenotype for db/AD and db animals. However, db/AD 
has been reported to have severe cognitive impairments relative to db animals (Niedowicz, 
Reeves et al. 2014). Our findings thus indicate that the cerebrovascular pathology seen in 
db/AD mice, believed to be responsible for their cognitive deficits does not lead to 
additional sleep aberrations.   
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Since sleep modulates energy metabolism, and the reverse holds true as well, some 
common neural circuits can be involved in regulating both sleep and metabolism  (Collet, 
van der Klaauw et al. 2016). Some of those neural pathways might be mediated through 
the hypothalamus, a brain region central to sleep regulation as well as energy homeostasis. 
A set of SCN neurons have been shown to project to the arcuate nucleus of the 
hypothalamus, which then forms reciprocal connections with orexigenic neurons 
expressing NPY/AGRP, and anorexigenic neurons expressing POMC and CART (Saeb-
Parsy, Lombardelli et al. 2000, Yi, van der Vliet et al. 2006, Huang, Ramsey et al. 2011). 
These neuropeptides are modulated by leptin- a satiety hormone under circadian regulation 
which is released in increased amounts at night (Sinha, Ohannesian et al. 1996, Licinio, 
Mantzoros et al. 1997).  
Leptin can be one of the upstream molecular components involved at the 
intersection of AD and diabetes. Leptin mediates its functions through JAK/STAT 
signaling pathway, activating kinases such as MAPK, AKT and mTOR (Marwarha and 
Ghribi 2012). These kinases are known to inhibit Glycogen synthase 3 Kinase (GSK3B) 
which then suppresses GSK3 dependent tau phosphorylation. Down-regulation of leptin 
signaling as seen in T2DM can therefore result in increased tau phosphorylation which can 
subsequently promote AD development (Chen, David et al. 2004). Niedowicz et al found 
that db/AD and db mice do in fact have upregulated tau phosphorylation along with 
increased PS1 expression. Unlike expected, these increased levels of PS1 were not 
accompanied by additional A deposition, either in the brain or in vasculature (Neidowicz 
et al., 2014). Though, A oligomers were found to be elevated in db and more so in AD/db 
mice. Hyperinsulinemic individuals have an increased tau phosphorylation, and are at a 
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higher risk of developing AD and cognitive decline (Luchsinger, Tang et al. 2004). Thus, 
another possible instigator of tau pathology can be insulin, the release of which is 
temporally regulated. 
Leptin also acts at the level of hippocampus and modulates synaptic plasticity and 
is presumed to be a cognitive enhancer. A study utilizing data from AD Neuroimaging 
Initiative (ADNI) reported low plasma leptin in 70% of subjects with MCI. Leptin 
treatment in AD mice reduces AD pathology, i.e. tau phosphorylation and amyloid beta, 
which consequently also improved cognition (Freude, Plum et al. 2005). The mechanism 
listed above, explaining the interplay among sleep, AD and db is possibly only one aspect 
of the complex cascade of events. There may be several yet unappreciated signaling 
pathways involved; with other neuroendocrine and metabolic components playing a critical 
role as well. For instance, GSK3, in addition to their involvement in the leptin pathway, 
also affects rhythm of clock genes in SCN (Avila, Leon-Espinosa et al. 2012, Besing, Paul 
et al. 2015). Reduction in leptin can result in upregulated GSK3 which might 
subsequently result in fragmented sleep, as found in transgenic mice overexpressing 
GSK3 (Ahnaou and Drinkenburg 2011). Orexin can be another possible component 
considering that is implicated in metabolism in addition to sleep. Inhibition of orexin 
system has been reported to not only improve sleep but also glucose metabolism in db/db 
animals (Tsuneki, Kon et al. 2016). Collectively, these studies suggest that diabetes 
associated dysfunctions promote AD pathology which can then disrupt sleep. Conversely, 
sleep impairments might be augmenting the AD and T2DM diseased states. Further 
interrogation of the underlying pathways can bridge the gap in our understanding of how 
sleep, AD and diabetes are inter-connected.  
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 In summary, our study indicate that AD mice tend to sleep less during night 
compared to control mice. In contrast, db genotype (db/AD and db) resulted in increased 
overall duration of sleep culminating from increased sleep duration at night. The db/AD 
mice are obese, insulin resistant and glucose intolerant, and have amyloid deposition 
similar to their parental lines. Furthermore, they also display additional cerebrovascular 
abnormalities, and reduction in A compared to AD mice, as have been reported in case of 
diabetic humans with AD-neuropathology. These mice thus emulate key aspects of human 
pathological condition and can well serve as model to interrogate how the interaction of db 
and AD leads to cerebrovascular abnormalities, and reduction in AD pathology.  
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Abstract  
Sleep is a critical process that is well-conserved across mammalian species, and 
perhaps most animals, yet its functions and underlying mechanisms remain poorly 
understood. Identification of genes and pathways that can influence sleep may shed new 
light on these functions. Genomic screens of sleep enable the detection of previously 
unsuspected molecular processes of sleep. In this study, we report on a large scale 
phenotyping of sleep-wake parameters for a population of single-gene knockout mice at 
The Jackson Laboratory, a primary production and phenotyping center for the Knockout 
Mouse Program (KOMP2). Sleep-wake parameters were measured using a high 
throughput, non-invasive piezoelectric. Knockout mice generated on a C57BL6/N (B6N) 
background were monitored for sleep and wake parameters for five days under baseline 
conditions. Thus far, we have recorded sleep in over 6000 mice representing over 300 
single gene knockout lines, and more than 1800 B6N control mice (females and males). 
Our study also integrated assessment of breath rates as a supplemental tool in determining 
aberrant physiology in these knockout lines.  Significant sleep-wake differences in both 
light and dark phases were found for a number of knockout lines compared to controls. We 
have identified more than 60 genes influencing various sleep traits which have not 
previously been implicated in sleep. Additionally, sex differences were found for B6N 
mice and many of the knockout mouse strains. Control females exhibited shorter bout 
lengths and less total sleep compared to males as reported by other studies. Further studies 
investigating these genes, their correlation with other phenotypes and interaction with other 
known sleep related genes can provide insight into the pathways regulating sleep and its 
associated functions.  
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Introduction   
Sleep is a complex behavior common to all birds and mammals, and probably most 
or all other vertebrates and invertebrates with a nervous system. Regulated by a multitude 
of neuronal processes and indirectly by gene networks, it is a process vital for an 
organism’s well-being. Sleep has been suggested to have a role in functions such as 
learning, memory consolidation, energy restoration, synaptic optimization and recently it 
has also been implicated in the clearance of metabolites, including amyloid beta (Aβ) 
(Tononi and Cirelli 2006, Tucker, Hirota et al. 2006, Marshall and Born 2007, Nishida, 
Pearsall et al. 2009, Diekelmann and Born 2010, Xie, Kang et al. 2013, Krueger, Frank et 
al. 2016). 
Genetic manipulations have advanced our knowledge about some aspects of sleep, 
including influences on the sleep EEG, sleep disorders, brain areas regulating sleep 
processes, and molecular pathways underlying sleep and its regulation. However, relatively 
few gene mutations or gene knockouts in mice have been examined for effects on sleep, 
and there are still many unresolved questions regarding the biological need for sleep, 
functions of sleep, and the genetic and physiological basis of sleep homeostasis that could 
be addressed with insights from model organisms (Rechtschaffen 1998, Cirelli 2009, 
Vassalli and Dijk 2009). 
There have been numerous efforts to address these questions utilizing a variety of 
animal models including mice. These efforts range from individual labs studying specific 
knockout mice, to large-scale QTL (quantitative trait loci) and genome-wide projects 
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including phenotype-driven ENU (N-ethyl-N-nitrosourea) mutant screens involving many 
labs, and gene-driven knockout mouse phenotyping programs (Gondo, Fukumura et al. 
2009). 
 
Circadian clock genes such as Clock and Rab3a in mice, and Per, and Dbt in flies, 
which influence both circadian timing and sleep homeostasis have been identified using 
ENU/EMS ( N-ethyl-N-nitrosourea/Ethyl methanesulfonate) mutagenesis techniques 
(Vitaterna, King et al. 1994, Kloss, Price et al. 1998, Kapfhamer, Valladares et al. 2002, 
O'Hara, Ding et al. 2007, Cirelli 2009). Discovery of these clock genes led to identification 
of many others (Bmal1/Cyc, Cry1,2, Per1,2,3, etc.) that also underlie circadian and 
homeostatic aspects of sleep. However, many of these mutations produce only subtle 
phenotypes, which are difficult to detect, and, in addition are also affected by the genetic 
background of the mouse (Nadeau 2001). Approaches using traditional mouse strains, 
genetic crosses, and QTL strategies have also identified a modest number of genes that 
influence sleep including Homer1a, Acads (acyl-coenzyme A dehydrogenase), and Rarb 
(Retinoic acid receptor beta) (Tafti, Petit et al. 2003, Drager 2006, Maret, Dorsaz et al. 
2007). A disadvantage of traditional QTL approaches is that they are subject to limited 
mapping resolution, and identifying the causal gene(s) is often difficult or not undertaken 
(Tabor, Risch et al. 2002, Churchill, Gatti et al. 2012), although this situation is improving 
with recent advances in mapping populations and related approaches (Jiang, Scarpa et al. 
2015).   
A major bottleneck in large scale genetic studies of sleep is the difficulty, expense, 
and time demands of traditional EEG/EMG studies. While knockout studies of selected 
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target genes such as neurotransmitter receptors have found modest effects on at least one 
sleep parameter, relatively few genes have been examined (O'Hara, Jiang et al. 2017).  
Using a higher throughput, non-invasive approach allows for much larger numbers of mice 
to be examined (Flores, Flores et al. 2007, Pack, Galante et al. 2007, Donohue, Medonza 
et al. 2008, Philip, Sokoloff et al. 2011, Mang, Nicod et al. 2014). Our approach utilizes a 
sensitive piezoelectric film across the mouse cage floor, and is especially well suited to 
characterization of large-scale resources such as the International Knockout Mouse 
Consortium (IKMC) (Ringwald, Iyer et al. 2011). IKMC aimed to generate mutant 
embryonic stem cells (ES) for every coding gene in the mouse genome on the B6N 
background. As live mice are made from the ES cell lines, these single-gene knockouts 
undergo a core set of broad-based phenotyping screens at the KOMP2 centers and as part 
of the International Mouse Phenotyping Consortium (IMPC) (Abbott 2010, Bradley, 
Anastassiadis et al. 2012, Brown and Moore 2012). At The Jackson Laboratory KOMP2 
Center (JAX-KOMP2) sleep is part of this pipeline, and the results thus far are described 
in this report. 
Methods and Design  
Generation of KO mice  
IKMC mouse mutants generated on a C57BL/6NJ mouse background have either 
null alleles, which have an entire locus removed or “knockout-first” alleles, which permits 
generation of conditional alleles by utilization of site-specific recombinase as described 
previously (Skarnes, Rosen et al. 2011, Schofield, Hoehndorf et al. 2012). Strain C57BL/6 
is a well-characterized inbred strain which also serves as a reference strain for the mouse 
genome, making it an ideal choice for this effort, although differences between the 
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C57BL/6J and C57BL/6NJ substrains exist (Keane, Goodstadt et al. 2011, Simon, 
Greenaway et al. 2013, Mekada, Hirose et al. 2015). Mice generated by the JAX-KOMP2 
effort are non-conditional (Tm1b) null alleles. Homozygous mutants were screened for 
sleep wake phenotype in this study. 
As part of the JAX-KOMP2 phenotyping pipeline, each mouse is comprehensively 
phenotyped for over 200 measurements, from age 4-18 weeks, for a range of 
morphological, physiological and behavioral traits including many disease relevant 
parameters pertaining to neurobehavior, metabolism, immune, cardiovascular, sensory, 
and musculo-skeletal systems, followed by terminal collection of blood and histopathology 
(Morgan, Simon et al. 2012) (Fig 1). Additional tests such as light/dark and hole-board 
exploration tests, rotarod, and sleep, are unique to the JAX-KOMP2 pipeline. Sleep is 
evaluated using a PiezoSleep System (Signal Solutions, LLC, Lexington, KY), a non-
invasive, high throughput sleep-wake monitoring system (details provided in following 
sections). The primary traits analyzed are total sleep duration averaged across 24 h, across 
the 12 h light phase and 12 h dark phase, and average sleep bout lengths (across 24 h, dark, 
and light phase), and breath rate during all sleep periods. 
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Figure 5 Phenotyping pipeline at The Jackson Laboratory 
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Sleep recording with piezoelectric system 
Sleep and wake states were determined using the PiezoSleep System (Flores, Flores 
et al. 2007, Donohue, Medonza et al. 2008, Mang, Nicod et al. 2014). The system is 
comprised of plexiglass cages lined with piezoelectric films across the cage floor that detect 
pressure variations. For all sleeping postures, pressure variations from breathing are 
detected. Sleep states are characterized by quasi-periodic signals with low variations in 
amplitude, whereas wakefulness and rest states are characterized by irregular transient and 
high amplitude pressure variations corresponding to voluntary body movements and 
weight shifting.  
Signal features sensitive to the differences between the sleep and wake states are 
extracted from 8-second pressure signal segments, and classification is automatically 
performed every 2 seconds using overlapping windows. Sleep-wake decisions in the 2-
second intervals are binned over specified time periods (e.g., 5 minutes, 1 hour) for local 
percent sleep/wake statistics.  In addition, durations of consecutive sleep states are used to 
compute mean sleep bout lengths. To eliminate the impact of short and ambiguous arousals 
on the bout length statistic, a bout length count is initiated when a 30-second interval 
contains greater than 50% sleep and terminates when a 30-second interval has less than 
50% sleep. The sleep bout length computed with the 50% wake in the 30-second interval 
rule typically marks a clear transition into an extended wake period, where the mouse does 
not quickly transition back into the sleep state. The piezo system has been validated with 
simultaneous EEG and human scoring of mice demonstrating a classification accuracy of 
over 90% in mice (Donohue, Medonza et al. 2008, Mang, Nicod et al. 2014). The sleep 
statistics analyzed under baseline (undisturbed) conditions for experiments summarized in 
this report were: percent sleep over 24 h periods, percent sleep during light phase, percent 
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sleep during dark phase, average sleep bout length (across 24 h, light phase, and dark phase 
periods), and mean breath rate during sleep. 
Animal housing and Phenotyping  
This study utilizes control and KO mice generated on B6N background. From wean 
age, mice were housed at 3-5 mice per pen in pressurized, individually ventilated cages 
using pine shavings as bedding, with free access to acidified water and food (LabDiets 
5K52, LabDiet, Scott Distributing, Hudson, NH). The housing facility was maintained on 
a 12:12 light/dark cycle starting at 0600. At 15 weeks of age, mice were removed from 
their home cages and placed into individual cages of the piezo system. The system used in 
the JAX-KOMP2 pipeline is comprised of 16 4-cage units, allowing assessment of up to 
64 mice per 5-day experiment. Light cycle and food and water access were as that of 
standard housing conditions. A minimum amount of pine shavings was provided to each 
cage to allow sufficient detection of pressure signal. In each testing week, 10 control B6N 
animals (five females and five males) and 3-19 animals per KO line were tested. Females 
and males of all KO strains were analyzed, with a pipeline throughput goal of testing eight 
animals of each sex for all screens. Data presented in this report includes 1884 B6N mice 
(Females= 960, Males= 924) and 4467 KO mice (2243 females and 2224 males) from 318 
KO strains. 
Analysis 
A data confidence metric that ranges from 0 through 1 assesses the signal quality 
and/or outlying signal behavior. Any of the sleep recordings with a data confidence value 
below the threshold of 0.6 was removed from the analysis. The control mice were also 
screened for outliers based on extreme high/low values for their sleep/wake parameters. 
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Control mice with Mahalanobis outlier distance (MD) above the upper control limit of 3.75 
were excluded from the analysis.  The final dataset used for analysis contained 1884 
Controls (960 Females; 924 Males), and 4467 KO (2243 Females; 2247 Males). One-way 
analysis of variance (ANOVA) was performed for each sleep variable and breath rate, and 
posteriori multiple comparisons were done using Dunnett’s test to identify genotypes 
showing significant difference/s with respect to the control group. Similar analysis was 
done to identify genotypes with sex-specific effects. 239 of the knockout cohorts 
containing at least 3 females and 3 males each were included in this analysis. For all of the 
sleep-wake parameters under consideration (listed above) measured, a P-value of less than 
0.05 was considered significant. Family-wise error rate was controlled by Dunnett’s test. 
Genotype was considered as an independent variable and the parameter under observation 
as the dependent variable. Initially, weight was accounted for as a co-variate. There was 
no effect of weight; therefore, it was excluded from the subsequent analysis. Also, 
multivariate outliers were identified using Mahalanobis distance (MD) in our data, as 
described elsewhere (Mitchell and Krzanowski 1985). In brief, it calculates 
multidimensional distance of each of the observations from the centroid mean vector of all 
measured variable scores, (Bassett, Gogakos et al. 2012).  
Principal components analysis (PCA) was performed on six of the sleep variables 
under consideration: sleep duration in the light and dark phases and across 24 hours, bout 
length across 24 h and bout length in the dark and light phase, and breath rate. PCA is used 
to reduce the number of variables into principal components (PC) that account for most of 
the variance of the original variables (as reported in terms of eigenvalue) and also to get 
insight into the patterns in the data. 
81 
 
We investigated relationships between results from the targeted knockout genes and 
some of the known circadian and sleep-influencing genes, by implementing a network 
analysis using GeneMANIA plugin (University of Toronto) with Cytoscape 
(version3)(Warde-Farley, Donaldson et al. 2010). 
Results 
B6N mice 
Mean values for sleep traits obtained from piezo system for B6N mice were 
established as a reference range, obtained separately for each sex. We found that female 
B6N have a significant reduction in total sleep time, as well as reduced sleep in both the 
light and dark periods (Fig 2A) compared to B6N males, though it is less pronounced 
during the light phase (p < 0.05) as compared to dark phase (p<0.05). The mean percent 
sleep across 24 h was 41.72 ± 0.11% for females and 45.09 ± 0.11% for males. During the 
dark phase, mean sleep duration was 21.49 ± 0.16% in females and 27.23 ± 0.17% in males, 
and in the light phase, for females sleep duration was 61.93 ± 0.15 % and 62.95 ± 0.14% 
in males. Similar to sleep duration patterns, females also show shorter bout lengths 
measured across 24 h (Females: 369.72 ± 1.98 s; Males: 444.56 ± 2.5 s), and during both 
the dark (Females: 199.48 ± 1.39 s; Males: 276.19 ± 2.16 s) and light phases (Females: 
537.22 ± 2.92 s; Males: 618.97 ± 3.48 s) (Fig 2B). Overall, B6N female mice have reduced 
sleep duration and shorter bout length than their male counterparts.  
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A. 
 
B. 
 
Figure 6 Sleep–wake patterns in control mice under baseline conditions. Average percent 
sleep across three consecutive days analyzed over (A) 24 h, dark phase, and light phase. 
Female mice show reduction in sleep duration across 24 h and during the light and dark 
phase. (B) depicts average bout length in seconds (s) over 24 h, dark phase, and light phase. 
Females had shorter average bout lengths across all phases. Values represent mean ± SD 
as obtained by Dunnett’s test. **P< 0.01, ***P < 0.001. 
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Knockout mice 
This report presents the analysis of piezo system sleep recordings from 318 KO 
strains (Figure 4). Of these, 55 KO strains showed significance at p<0.01 in Dunnett’s post 
hoc analysis for one or more of the sleep variables recorded. Across the 24-hour period, 
reduction in sleep percent (total sleep) was observed in Ap4e1, Bzw2, Pitx3, Ppp1r9b, and 
Vsig4 KO strains, while increased total sleep was seen in Ccl26, Cbln3 and Tpgs2 
compared to control mice. During light phase, the reduced sleep percent was recorded in 
Kcnh3, Pitx3, Ppp1r9b, Hsd17b1, Htr3b, Nrcam, Tmem79 and Bzw2, and longer sleep 
duration in Bex4, Ccl26, Cdk15, Cpb1, Dnaja4, Eogt, Epgn, Epha10, Foxo3, Gjd4, Htr1f, 
Ifnl3, Ncald, Neurl2, Npm3, Rab3ip, Rimklb, Serpinb5, Slc46a3, Slc8b1, Tdrkh, Ttll6, Ydjc, 
Zbtb4, Zfp961 and Zbtb4 KO mice. During dark phase, sleep durations was reduced for 
Mylip, Ppp1r9b, Rimklb, and Vsig4 knockouts, and increased for Macrod2, Cbln3, Myh1, 
and Postn. Additionally, as compared to controls, mean bout length was significantly 
reduced across 24h in Ap4e1, Pitx3, Ppp1r9b, Hsd17b1, Myh1 and Rnf10, and increased in 
Tmem136 mutant mice. In light phase, bout lengths were significantly shorter in Ap4e1, 
Hsd17b1, Myh1, Nrcam, Ptpru, Pitx3 and Ppp1r9b, and longer in Adck2, Arrb2, Ermp1, 
Htr1d, Ipp, Nfatc4, Slc8b1, Tmem136, Tmem79 and Zfp961 relative to control mice. During 
dark phase, significantly shorter mean bout lengths were seen in Ap4e1, Bex4, Mylip, Nefh, 
Nes, Ppp1r9b, Rab27b, Rimklb, Rnf10, Rnf25, Stx16, Tmem151b, Tmod2, and Zzef1, and 
longer bout lengths were found in case of Ghrhr (Fig 3 and Table 1).  
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Figure 7 Represents mutant mice that differed significantly from control mice in percent 
sleep across 24 h (A), in light phase (B) and in dark phase (C); and bout length (D, E, F) 
across respective phases. (G) KO strains that differed significantly compared to control 
mice in their breathing rates. 
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B. 
 
Figure 8 Represents complete dataset for all 318 KO strains arranged alphabetically for 
(A) sleep percent (24h, dark phase, light phase), and (B) bout length (24h, dark phase, 
light phase) measured in seconds as depicted on y axis. Each bar represents mean (dot) ± 
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Similar analysis was performed for 239 KO strains, each of which had at least 3 
females and 3 males to evaluate sex-specific differences in sleep parameters measured. The 
results for Pitx3 are similar to that observed in the overall data. In both males and females, 
as compared to controls, Pitx3 has significantly lower sleep percent and bout length only 
during the light phase. Ppp1r9b, though significantly reduced for overall sleep percent in 
both males and females, was not found to be significant in both males and females for bout 
lengths during the light phase. Myh1 had reduced sleep percent and bout lengths during 
light phase in males and higher sleep percent in females. Hsd17b1 had reduced sleep 
percent in males and reduced bout lengths in both males and females only during the light 
phase. Increased sleep percent was seen in both males and females in Postn during dark 
phase, and Slc8b1 during light phase. Cbln3 and Ccl26 had increased sleep percent in 
females with Ccl26 affecting sleep only during the light phase and Cbln3 affecting both 
light and dark phases. Significantly higher sleep percent during light phase were seen in 
females belonging to Cpb1, Serpinb5, Slc46a3, and Ydjc, while reduced values were seen 
in Col18a1. Adck2 and Ptpru have significantly lower sleep percent during light phase 
while it is increased in Ipp, Nrn1l, and Tmem136. Zbtb4 had increased values for sleep 
percent and bout lengths during the light phase in females, whereas Vsig4 and Ghrhr had 
significantly reduced values during the dark phase. Among the genotypes specific to males, 
Dnaja4 and Epha10 have significantly higher values for sleep percent, while it is reduced 
in Prom2 during the light phase. Bout lengths are significantly reduced specifically during 
dark phase in Ap4e1, Rimklb, Rnf10, Stx16 and Zzef1. In Zfp961 males, sleep percent and 
bout length are both increased during the light phase in males while they are lower during 
the dark phase in Tmem151b and Tmod2 males. 
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Table 6 Sex differences in genotypes significant for (A) sleep percent and (B) bout lengths  
with direction of change.  represents values higher than Control animals, and  represent 
values lower than Controls. 
A. 
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B. 
 
Prinicpal Component and Outlier Analysis 
 We performed additional analyses to identify sleep related genes based on multiple 
measures using Principal Component Analysis (PCA) . We included standardized values 
for sleep percent and bout lengths for 24 hours, light phase and dark phase in our analysis. 
For our dataset, as can be seen from the scree plot, the first three principal components had 
eigenvalues greater than 1 (a conventional threshold rule of thumb) and explained for more 
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than 95% variability in the data, with PC1 accounting for 46.92% of the variability (Fig. 
5). Correlation between the principal component and the original variables is described in 
terms of loadings. There is a point of inflection in the eigenvalues after 4 components. 
However, fourth factor has eigenvalue less than 1, indicating that 3 components may best 
represent the data. Biplot reveals the relationship between different sleep variables in first 
two principal components.  
The first PC1 had high loading values for each variable (mean loading = 0.68; 
Figure 5C). ANOVA with multiple comparison through Dunnett’s post hoc test of PC1 
resulted in 9 genotypes that showed significance. These genotypes are Pitx3, Ppp1r9b, 
Ap4e1, Hsd17b1, Rnf10, Ghrhr, Fam186b, and Tnfsf18. Interestingly, the PC2 had positive 
loadings for sleep percent and negative loadings for bout lengths, and Tpgs2, Tmem79, 
Cbln3, Myh1, Ppp1r9b, Parp8, Rnf25, Arrb2, Macrod2, Dcaf10, and Ccl26 were 
significant. Similarly, PC3 had positive loadings for light phase and negative loadings for 
dark phase. In addition to others, the genes significant for PC3 include Pitx3, Rimklb, 
Zfp961, Postn, Hsd17b1, Slc8b1, Serpinb5, Nrcam, Cpb1, Macrod2, Ipp, Dnaja4, and 
Mylip. Based on the results from ANOVA of individual variables and PC3, we propose 
these genes as candidate genes that affect sleep in a specific circadian phase. 
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A. scree plot      B: Biplot 
 
C.  Loading matrix for PCs 
Figure 9 Scree plot depicting relationship between eigenvalue and number of 
components. 
Outlier Analysis 
As an additional outlier detection strategy, Mahalanobis distances (MD) for multivariate 
outliers were calculated for the sleep percent and bout length variable means of all KO 
strains and candidate genes were identified with upper control threshold of 3.75. Based on 
outlier analysis, the top candidate genes for sleep are Pitx3, Ppp1r9b, Ap4e1, Akr1d1, 
Postn, Myh1, Tnfsf18, Ptpru, Mdk, Vsig4, Tmem79, Serpinb5, Ipp, Bex4, Gpr156, Stat5b, 
Hsd17b1, Plekha3, Esrra, Gpr19, Stx16, Slc1a1, Actrt3, Rabac1, Tpgs2, Arrb2, and Ghrhr. 
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Gene Network Analysis 
To further evaluate genes with significant sleep phenotypes discovered in our study, 
and to compare these to genes known to affect sleep, we used the GeneMANIA tool 
(Warde-Farley, Donaldson et al. 2010), implemented in Cytoscape software (version 3). 
The GeneMANIA application determines relationships between the query genes and other 
related genes based on their genetic and physical associations, shared protein domains, co-
expression, co-localization and their participation in the shared pathways. Predictive gene 
networks were created as depicted in Figure 6, using candidate genes from our analysis 
with respect to the key genes previously implicated- Arntl, Clock, Per1, and Per2 in 
regulation of sleep behavior.  
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Figure 10 Gene networks as predicted by GeneMANIA based on genetic and physical 
associations, shared protein domains, co-expression, co-localization and their participation 
in the shared pathways for the candidate genes of interest with respect to the genes that are 
known to affect sleep- Arntl, Clock, Per1 and Per2. 
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Breath Rate 
Breath rate significantly differed from controls for 34 of the strains (p< 0.05) (Fig 
3G and Table 1C). A few of these mice displayed a sleep phenotype in addition to varied 
breath rate and include knockouts for genes: Myh1, Nes, Cbln3, Htr1f, Slc8b1, Tdrkh, 
Rab3ip, Slc46a3, Adck2, Postn, Tmod2, Cbln3, Nes, Dnaja4, and Stx16. Sex differences 
were found for breath rate as well. 
Discussion 
We have reported here the results from a large-scale phenotyping study that 
systematically assesses sleep in knockout mice. With sleep wake recordings from more 
than 6000 mice, consisting of more than 1800 controls and nearly 300 gene knockouts, the 
KOMP2 pipeline at The Jackson Laboratory has generated a wealth of information-rich 
gene centric data that is unprecedented in sleep research. Through our analysis, we have 
been able to identify sleep-related genes that have been previously unknown to influence 
sleep. An experimental design using both sexes, and piezo monitoring system that 
consistently reports multiple sleep variables, has allowed for an in-depth analysis to 
identify genes that affect sleep in one or both sexes and during specific times of day. We 
found a considerably high hit rate with nearly 20% of gene knockouts tested differing 
significantly from controls for at least one sleep phenotype. This is perhaps not surprising 
given the dramatic changes in brain physiology and function that occur with sleep and wake 
transitions, and further suggests a potential to uncover many as yet unappreciated pathways 
affecting sleep. Although the purpose and functions of sleep are still unclear, we know that 
sleep is an essential physiological process and that even modest reductions in sleep have 
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substantial effects on health and cognitive functions (Shaw and Franken 2003, Durmer and 
Dinges 2005, Cohen, Doyle et al. 2009, Cespedes, Bhupathiraju et al. 2016).  
The key findings from data in this report are best exemplified by results obtained 
from Pitx3, Ppp1r9b Slc1a1, and Ap4e1 knockout mice that have a significant effect across 
many sleep traits. Pitx3 is the Paired Like Homeodomain Transcription Factor 3 and its 
deletion was associated with reduced sleep and bout length across 24h and light phase in 
our study. Although little is known about the role of Pitx3 and sleep, Derwinska et al have 
reported that a hemizygous deletion on chromosome 10 involving Pitx3 resulted in sleep 
disturbances beginning early childhood in a Caucasian boy (Derwinska, Mierzewska et al. 
2012). In addition, Pitx3 is well known for its role in regulating lens development and is 
therefore associated with ocular abnormalities as seen in a range of animals including 
xenopus, zebrafish, humans as well as mice where its deficiency is reflected as a form of 
aphakia (Flint, Valdar et al. 2005, Harper, Volicer et al. 2005, Hirai, Pang et al. 2005, 
Khosrowshahian, Wolanski et al. 2005, Shi and Chiang 2005, Shi, Bosenko et al. 2005, 
Laposky, Shelton et al. 2006, Popov, Kaminskaya et al. 2009, Huang and He 2010, 
Bertram, Rook et al. 2011, Bertram and Rook 2012, Callander, Bolton et al. 2012, Mavanji, 
Billington et al. 2012, Dyakonova and Krushinsky 2013, Reichert and Gerhardt 2013). In 
the KOMP2 pipeline, in addition to sleep, Pitx3 is associated with a multitude of 
phenotypes including vision/eye, neurological/behavior, growth/size, 
homeostasis/metabolism, cardiovascular and skeleton. As expected, the Pitx3 KO mice 
have anopthalmia or absence of eyes. In mice, Pitx3 is also thought to be essential in 
development of dopaminergic neurons in Substantia Nigra (SN). Besides SN, Pitx3 is also 
expressed in Ventral Tegmental area (VTA)  Reviewed by (Peirce, Lu et al. 2004, Maret, 
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Dorsaz et al. 2007, Chandran, Shahana et al. 2009, Cirelli 2009, Cohen, Doyle et al. 2009, 
Deschenes and McCurry 2009, Gondo, Fukumura et al. 2009, Kang, Lim et al. 2009, 
Koethe, Schreiber et al. 2009, Kroner 2009, Li, Dani et al. 2009, Mekada, Abe et al. 2009, 
Millstein, Zhang et al. 2009, Miura, Matsuda et al. 2009, Miyake, Takahashi et al. 2009, 
Moy, Nonneman et al. 2009, Nishida, Pearsall et al. 2009, Ohno 2009, Panda, Patra et al. 
2009, Perrin, Fagan et al. 2009, Popov, Kaminskaya et al. 2009, Regal, Amigo et al. 2009, 
Sorensen, Vermeulen et al. 2009, Vassalli and Dijk 2009, Walker 2009, Winrow, Williams 
et al. 2009, Wisor, Jiang et al. 2009, Devi and Ohno 2010, Sheline, Raichle et al. 2010, 
Wang, Liu et al. 2010, Rillich, Schildberger et al. 2011, Bertram and Rook 2012, Callander, 
Bolton et al. 2012, Dyakonova and Krushinsky 2013, Fitzsimmons and Bertram 2013, 
Reichert and Gerhardt 2013, Stevenson and Schildberger 2013). Not only these regions are 
associated with reward, addiction and movement, they also play an important role in sleep 
and alertness Reviewed by (Nishino 2013). 
Ppp1r9b is the Protein Phosphatase 1 Regulatory Subunit 9B (or Neurabin II or 
Spinophilin), and as the name indicates is a regulatory subunit of protein phosphatase 
(PP1). It is a protein highly enriched in dendritic spines (Feng, Yan et al. 2000). Sleep is 
reported to promote formation of dendritic spines for memory consolidation (Yang, Lai et 
al. 2014). In addition, PP1 regulates AMPA channels that are believed to play a role in 
synaptic plasticity, and learning and memory Reviewed in (Prince and Abel 2013). Further, 
Ppp1r9b is one of the substrates of GSK3B (Glycogen Synthase Kinase 3 Beta) which is a 
crucial circadian clock regulator (Kaasik, Kivimae et al. 2013). Casein Kinase I enzymes 
have been shown to play a critical role in regulating clock genes such as Per2, and Ppp1r9b 
may dephosphorylate some of these same sites and work in opposition (Fukuyama 2003 
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and Padiath 2005). There is increasing evidence that clock genes not only influence 
circadian aspects of sleep and wake, but are fundamentally tied to sleep homeostasis as 
well, which appears to be altered in the Ppp1r9b knockout mice (Flores, Flores et al. 2007, 
Franken, Thomason et al. 2007, Maret, Dorsaz et al. 2007, O'Hara, Ding et al. 2007, Curie, 
Mongrain et al. 2013, Franken 2013, Mang and Franken 2013).  
Ap4e1 codes for the Epsilon subunit 1 of Adaptor Protein (AP) 4 complex that is 
involved in vesicle trafficking. Ap4e1 has been associated with Cerebral Palsy, and 
mutations in humans have been known to cause intellectual disabilities, of which abnormal 
sleep behavior is one of the symptoms (Moreno-De-Luca, Helmers et al. 2011). Like Pitx3, 
Ap4e1 is associated with multiple additional aberrant phenotypes observed in the KOMP2 
pipeline, and is also found to be within the QTL Cplaq15 (Circadian Period of Locomotor 
Activity 15) (Hofstetter, Trofatter et al. 2003).  
Another KO that showed significant changes in sleep-wake traits is Kcnh3 (Kv12.2) 
a subunit of potassium channels that regulate neuronal excitability. Kcnh3 KO mice have 
shorter sleep duration in the light phase. A similar but less pronounced reduction was also 
seen in Kcnh3 heterozygous mice (data not included). Its overexpression has been 
associated with deficits in learning, and its ablation with enhanced cognitive functions 
(spatial and working memory), hippocampal hyperexcitability and spontaneous seizures 
(Miyake, Takahashi et al. 2009, Zhang, Bertaso et al. 2010). Many other Kv channels are 
known to modulate sleep-wake. A well-known example is Shaker in drosophila (Cirelli, 
Bushey et al. 2005). Flies mutant for the Shaker gene have reduced sleep and are short 
sleepers. In Kcnc1, Kcnc3, Kcnc1/3 and Kv1.2 KO mice less NREM sleep has been 
observed, with a similar magnitude to sleep phenotypes observed for Kcnh3 reported here 
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Reviewed in (Rechtschaffen 1998, Cirelli 2009). Hence, our study identifies and adds 
another novel potassium channel associated gene that affects sleep. Lack of certain K 
channels may reduce the resting membrane potential of neurons, leading to increased 
firing, and reduced sleep. While this would occur in both inhibitory and excitatory circuits, 
the net effect is presumably increased excitation. Recently, Ding et al has shown that 
reduction seen in brain extracellular potassium ion levels is associated with sleep and 
anesthetized mice supporting this hypothesis (Holth, Patel et al. , Cespedes, Bhupathiraju 
et al. 2016, Ding, O'Donnell et al. 2016, Yaghouby, Donohue et al. 2016).  
Slc1a1 (EAAC1 or EAAT3), a glutamate transporter is found mainly in neurons. 
Lack of this transporter may increase glutamate transmission, and similar to the K channel 
story, may lead to greater excitatory responses and more difficulty falling asleep (Kanai, 
Bhide et al. 1995, Aoyama and Nakaki 2013).  Slc1a1 knockout mice have both lower sleep 
amounts and shorter bout lengths.   
Nrcam KO mice have reduced sleep and bout length during light phase. Nrcam 
(Neuronal cell adhesion molecule), a neuronal cell adhesion molecule, serves many 
functions such as axonal guidance, clustering, and maintenance of sodium channels 
essential for action potential propagation at nodes of Ranvier (Sakurai 2012, Amor, 
Feinberg et al. 2014). It also regulates density of dendritic spines (Demyanenko, Mohan et 
al. 2014). Nrcam has been shown to be associated with autism in humans as Reviewed in 
(Sakurai 2012). Cognitive deficits were also found in Nrcam null mutant mice (Reviewed 
in (Moy, Nonneman et al. 2009). 
Cbln3 KO mice had increased duration of sleep across 24 hours and dark phase. 
Cbln3 belongs to precerebellin family and studies conducted by Miura and colleagues show 
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that it co-localizes at purkinjee cell synapse along with Cbln1, another cerebellum specific 
protein, important for synaptic plasticity (Hirai, Pang et al. 2005, Miura, Matsuda et al. 
2009). 
With a multitude of phenotypes and rich data in the KOMP2 pipeline, cross trait 
analysis is the logical extension of this study. As an initial step, we conducted cross trait 
analysis between sleep and neurobehavioral phenotypes performed as part of the JAX 
KOMP2 pipeline. In the 38 KO strains we identified with abnormal sleep, we found 
significant associations with abnormal behavioral responses to light and hyperactivity. 
Specifically, Chn1, Rnf10, Rimklb, Ap4e1, and Macrod2. Pitx3, Foxo3, Ccl26, and Ghrhr 
were associated with abnormal behavioral response to light, and Mylip, Nxn and Zbtb4 to 
hyperactivity. Ppp1r9b had abnormal responses to new environments, whereas Mylip and 
Pitx3 showed increased exploratory activity in new environments. Startle reflex was 
increased in Pitx3, Ajap1, and Nxn, while it was decreased in Foxo3. As seen with the gene 
networks, several of these genes have a circadian footprint and may contribute to these 
coincident phenotypes. 
Sex differences were seen for many of the KO lines as well as in B6N controls 
throughout our study. Previous studies in mice and humans also report similar sex 
differences in sleep and circadian rhythms, although with relatively small sample sizes. 
Sex differences in sleep have also been observed in BL6J mice for baseline sleep 
parameters such as REM and NREM sleep, with lower values observed in female mice 
(Koehl, Battle et al. 2006, Paul, Dugovic et al. 2006). Sex differences observed in human 
studies have generally been small, but include higher EEG power density in women 
(Carrier, Land et al. 2001). EEG profiles in primary insomnia patients also show sex 
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differences (Buysse, Germain et al. 2008). Sex hormones are thought be one of the 
contributing factors for these differences (Collop, Adkins et al. 2004, Krishnan and Collop 
2006, Pavlova and Sheikh 2011). 
In addition to small but significant sex differences in our control mice, several 
genotypes had highly significant sleep trait differences for a specific sex. KO strains in 
which sex differences were found might be helpful in identifying causes for the intriguing 
sexual dimorphism seen in sleep behavior, such as those in which female mice sleep less 
than males. In our data, the majority of significant findings are sex specific, suggesting at 
least some biochemical differences in female vs. male sleep regulation.  
Our study demonstrates the utility of rapid-non-invasive sleep phenotyping in high 
throughput mouse screens. This initial set of approximately 300 genes was not selected to 
have sleep phenotypes and yet a high percentage were found to have altered sleep 
phenotypes, and of a magnitude as large as any that have been selected specifically for 
sleep studies over the past 25 years (Reviewed by (Cirelli 2009). This supports the utility 
of an unbiased selection and phenotyping for mouse knockouts, especially given that a 
majority of genes are not well understood. Unlike most individual studies of KO mice that 
examine genes predicted to influence a trait of interest, the IMPC/KOMP2 is a 
comprehensive, unbiased approach, having examined more than 2000 genes to date, and 
thus holds potential for detecting and identifying unexpected and pleiotropic effects of the 
knocked out genes (Brown and Moore 2012).With fewer than 300 KOs analyzed to date, 
we demonstrate the potential of this large scale effort to find novel sleep phenotypes for a 
significant percentage of coding genes.  
 
104 
 
Some of the potential sleep regulating genes identified in our study can be broadly 
categorized into transcription factors (Pitx3, Foxo3), immune system related (Ccl26), 
membrane transporters (Slc46a3, Slc8b1) ion channels (Kcnh3), neurotransmitters 
receptors (Htr3b, Htr1f, Htr1d), signal transduction (Ppp1r9b, Rab27b, Ap4e1), and 
metabolism (Ghrhr). A wide variety of genes belonging to these functional categories have 
been previously implicated in influencing sleep parameters. Furthermore, these categories 
are likely not exhaustive. Several of these genes have brain-associated functions such as 
myelin formation, neuronal differentiation, synaptic transmission, neuronal signal 
transduction and yet for many others such as Adck2 and Zfp961, there is little information 
available in the literature. None of the target genes, with the exception of Ghrhr and Pitx3, 
have been implicated in sleep regulation before to the best of our knowledge. Continued 
broad phenotyping for sleep in this resource is likely to open many new avenues for sleep 
research. 
There are some limitations to this study. The current analysis software does not 
distinguish REM sleep from NREM sleep, however, an algorithm to distinguish these sleep 
states from the piezoelectric recordings is in development and will be utilized in future 
studies once it has had sufficient validation. This algorithm and others will also be used to 
re-analyze data from the present study. Although we were able to detect many novel genes, 
the extensive filtering of sleep signals used in our study most likely excluded genes 
affecting sleep in subtle ways. Genes involved in sleep that have extensive redundancy or 
compensatory mechanisms in place to mask the effect of a gene ablation would also be 
missed. Finally, the knockout method is in general limited by the fact that a gene is ablated 
in all tissues, so KO of essential genes that may in fact be involved in sleep result in a non-
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viable animal, preventing sleep phenotyping. However, utilization of the conditional allele 
obtained from these KOs in the future may overcome this limitation.  It is also unclear to 
what extent any of the sleep alterations from gene ablation are due to direct or indirect 
effects of the gene in question. These questions may be partially addressed by examining 
the multiple phenotypes for each knockout, and can be pursued in other ways for the most 
interesting cases. There is no reason to believe that there are any genes whose sole functions 
are related to sleep, as even the so-called core circadian clock genes are pleiotropic.   
Because the piezoelectric system monitors breath rate as the primary movement 
during sleep, it may also be useful to detect sleep apneas. There is limited overlap between 
genotypes significant for sleep wake alterations, and those for breathing rate. The results 
thus far suggest it is not a variable directly related to sleep percent and bout length, and so 
it was excluded from PCA and MD analysis. The non-invasive nature of the piezo set up 
allows assessment of breathing without the stress of most other alternative methods for 
assessing breathing.  
 Several genes were found to affect breath rate. Majority of these genes affected 
breath rate only as is the case with Tppp (p25 alpha/p24) mice which had shorter breath 
rate.  A study conducted by Lehotzky et al suggests that Tppp, a tubulin-binding protein 
plays an important role in oligodendrocyte differentiation (Lehotzky, Lau et al. 2010). In 
addition, it also functions as a glycogen synthase kinase 3 inhibitor (Martin, Vazquez et al. 
2002, Reichert and Gerhardt 2013). However, some of the genes that affect breath rate 
were also implicated in influencing various aspects of sleep phenotype. For instance, Nes 
mice have reduced breath rate compared to control mice as well as shorter bout length 
during dark phase. Nestin is an intermediate filament protein expressed predominantly in 
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the initial developmental stages of stem cells of the CNS as well as skeletal muscle 
(Frederiksen and McKay 1988, Lendahl, Zimmerman et al. 1990, Sejersen and Lendahl 
1993).  
We don’t know yet if breath rate regulating mechanisms are in any way 
associated with other brain functions or sleep-related pathways, but the ability to assess 
breathing should provide additional variables of interest to the larger efforts to understand 
the multiple roles of all protein coding genes.   
Conclusions 
This study utilizes data generated from the KOMP2 project at The Jackson 
Laboratory, a large-scale project intended to phenotype knockout mice in alignment with 
the IMPC. This study reports on 6000 mice representing 300 different gene knockouts, 
along with over 1800 BL6NJ control mice all assessed for sleep and wake as a unique part 
of the JAX phenotyping pipeline. Our findings showed altered sleep and wake in many of 
the knockout lines compared to the controls.  
 Many of these strains also exhibit sex differences in sleep traits. In all, we identified 
a large number of genes in which target deletion resulted in high to modest effects on one 
or more of the observed sleep-wake traits, as well as breath rate. Follow up of these 
potential sleep regulating and breath rate modulating genes will likely suggest new 
signaling pathways underlying these two processes.  
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Sleep % 
24h 
Dark 
Sleep% 
Light 
Sleep% 
Bout Length 
24h 
Dark Bout 
Length 
Light Bout 
Length 
Breath 
Rate 
Genotype p-Value p-Value p-Value p-Value p-Value p-Value p-Value 
1700016K1
9Rik 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
4921509C19
Rik 0.99962 1.00000 0.11773 1.00000 1.00000 1.00000 1.00000 
A1cf 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Abca7 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Abcg2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Acap1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Acsf2 1.00000 1.00000 1.00000 0.86965 0.99985 1.00000 0.00016 
Acsm2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Actrt3 0.99971 1.00000 0.98181 1.00000 1.00000 1.00000 1.00000 
Adad2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Adck2 1.00000 1.00000 0.17446 1.00000 1.00000 0.00806 0.03159 
Adck5 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Adgrb2 1.00000 1.00000 0.33340 1.00000 1.00000 1.00000 1.00000 
Adora2b 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ahrr 1.00000 1.00000 1.00000 1.00000 1.00000 0.99997 1.00000 
AI464131 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ajap1 1.00000 1.00000 0.32801 1.00000 0.44121 1.00000 0.10606 
Akap11 0.99984 1.00000 0.76679 1.00000 1.00000 1.00000 1.00000 
Akip1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
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Akr1b8 1.00000 1.00000 0.95400 1.00000 1.00000 1.00000 1.00000 
Akr1d1 1.00000 1.00000 1.00000 1.00000 0.99940 1.00000 1.00000 
Ap4e1 0.00076 0.21807 0.05671 0.00048 0.00221 0.00760 0.99971 
Arf2 1.00000 1.00000 0.93698 1.00000 1.00000 0.04677 0.99992 
Arhgef10 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Arrb1 1.00000 0.67450 1.00000 1.00000 1.00000 1.00000 0.68630 
Arrb2 0.32676 0.05610 1.00000 1.00000 1.00000 0.04312 1.00000 
Arrdc1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.99964 
Arsk 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Asb10 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Bbox1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
BC030499 0.79457 1.00000 0.54030 1.00000 1.00000 1.00000 0.04413 
BC100451 1.00000 1.00000 0.37081 1.00000 1.00000 1.00000 0.97249 
Bex4 1.00000 1.00000 0.02559 0.77634 0.02136 1.00000 0.74879 
Bhlhe40 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.99953 
Bmp2k 1.00000 1.00000 1.00000 0.99997 0.99442 1.00000 1.00000 
Btg2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Bzw2 0.01586 1.00000 0.00405 1.00000 1.00000 0.86152 0.17542 
C1qa 1.00000 1.00000 1.00000 0.99993 1.00000 0.99804 0.00003 
C1qb 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.15766 
C1qtnf5 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.25933 
C3 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.99842 
C9 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Car12 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Carf 0.99883 1.00000 0.43063 1.00000 0.97268 1.00000 0.00060 
Cast 1.00000 1.00000 1.00000 0.79872 1.00000 0.85807 1.00000 
Cbln3 0.00048 0.00081 0.99998 1.00000 1.00000 1.00000 
<0.00001
 
Ccdc120 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ccl26 0.00161 0.88741 0.00451 1.00000 1.00000 0.83682 1.00000 
Cd33 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Cd84 0.84255 1.00000 0.70273 1.00000 1.00000 1.00000 0.02760 
Cdh4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Cdk15 0.05326 1.00000 0.04206 1.00000 1.00000 1.00000 0.52529 
Cdk19 1.00000 1.00000 0.98743 1.00000 1.00000 1.00000 1.00000 
Ceacam16 0.84604 0.99926 1.00000 1.00000 1.00000 1.00000 1.00000 
Cers5 0.73257 1.00000 0.18859 1.00000 1.00000 1.00000 0.03310 
Ces4a 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.09808 
Cfb 1.00000 1.00000 0.92660 1.00000 1.00000 1.00000 0.00702 
Chek2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
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Chn1 0.13375 0.99862 0.53975 0.99981 0.99972 1.00000 1.00000 
Cited4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Cldn13 1.00000 1.00000 0.65678 1.00000 1.00000 0.10247 0.98646 
Cldn19 1.00000 1.00000 1.00000 1.00000 0.99999 1.00000 1.00000 
Clvs1 1.00000 0.99994 1.00000 1.00000 1.00000 0.86035 0.77300 
Cml2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Col18a1 0.99999 1.00000 0.88021 1.00000 1.00000 1.00000 1.00000 
CONTROL 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Cp 1.00000 1.00000 0.99663 1.00000 1.00000 1.00000 1.00000 
Cpb1 1.00000 1.00000 0.00126 1.00000 0.88755 0.99035 0.92633 
Crym 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.02616 
Cyb5d1 1.00000 1.00000 0.58110 1.00000 0.99866 1.00000 1.00000 
Cyb5d2 1.00000 1.00000 0.99854 1.00000 1.00000 1.00000 0.99938 
Dcaf10 1.00000 1.00000 1.00000 0.15692 0.05769 1.00000 0.00008 
Dennd2d 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.87328 
Dixdc1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Dnaja4 1.00000 1.00000 0.00039 1.00000 0.99990 0.52167 0.00003 
Dnajb3 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Dnajb7 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.95353 
Dnajc14 1.00000 0.41574 0.69828 1.00000 0.99999 1.00000 0.99975 
Dnajc28 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Dnajc5g 1.00000 1.00000 1.00000 1.00000 1.00000 0.99957 0.85968 
Dnajc7 1.00000 1.00000 1.00000 0.96069 0.99463 1.00000 0.03437 
Dnase1l2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Dntt 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Dpf1 1.00000 1.00000 0.99997 0.99392 1.00000 0.99969 1.00000 
Elk1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.99999 
Eogt 1.00000 1.00000 0.01830 1.00000 1.00000 0.70973 0.99682 
Epb4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Epgn 1.00000 1.00000 0.00406 1.00000 0.99960 0.99923 0.29782 
Epha10 1.00000 1.00000 0.02732 1.00000 1.00000 0.98108 0.89822 
Ermp1 1.00000 1.00000 1.00000 1.00000 1.00000 0.01685 1.00000 
Espnl 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.99999 
Esrra 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
F2rl1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Fam161a 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.20642 
Fam186b 0.98672 1.00000 0.99980 0.21741 0.99658 0.05921 1.00000 
Fam217b 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Far2 0.85965 1.00000 0.95150 1.00000 1.00000 1.00000 0.99488 
Fastkd5 1.00000 1.00000 0.98823 1.00000 1.00000 1.00000 1.00000 
110 
 
Fdxacb1 1.00000 1.00000 0.96367 1.00000 0.99998 1.00000 0.16071 
Foxi2 0.99915 1.00000 0.09700 1.00000 1.00000 1.00000 0.06559 
Foxo3 0.99170 1.00000 0.00847 1.00000 1.00000 0.98206 1.00000 
Foxred2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ghrhr 0.73473 0.05054 1.00000 0.74584 0.00048 1.00000 1.00000 
Ghsr 1.00000 1.00000 0.99846 1.00000 1.00000 1.00000 1.00000 
Gimap6 0.96312 1.00000 0.10616 0.99961 0.86516 1.00000 0.97581 
Gimap8 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Gipc3 1.00000 1.00000 0.12197 1.00000 1.00000 0.15981 0.99964 
Gjd4 0.97336 1.00000 0.02652 1.00000 0.99824 1.00000 0.80596 
Glycam1 1.00000 1.00000 1.00000 0.99956 0.88946 1.00000 1.00000 
Gpnmb 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Gpr142 1.00000 1.00000 1.00000 0.99561 0.54208 1.00000 1.00000 
Gpr156 0.98860 1.00000 1.00000 1.00000 0.99999 1.00000 1.00000 
Gpr183 1.00000 1.00000 0.92334 1.00000 1.00000 1.00000 1.00000 
Gpr19 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
H1fx 1.00000 0.99983 0.99999 1.00000 0.34013 0.99422 1.00000 
Hc 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Hdac10 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Hemgn 1.00000 0.99991 1.00000 0.95509 0.10681 1.00000 1.00000 
Heyl 1.00000 0.99891 1.00000 1.00000 1.00000 1.00000 1.00000 
Hfe2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Hsd17b1 1.00000 0.99632 0.00003 <0.00001 1.00000 <0.00001 1.00000 
Hsd17b11 1.00000 1.00000 0.51096 1.00000 1.00000 1.00000 0.45232 
Hsf2 1.00000 1.00000 1.00000 1.00000 0.99900 1.00000 0.99991 
Hsf4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Hspb1 1.00000 1.00000 1.00000 0.99991 0.96012 1.00000 0.99969 
Hspb2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Hspb3 1.00000 0.99942 1.00000 0.98860 1.00000 1.00000 1.00000 
Htr1a 1.00000 1.00000 0.79472 1.00000 1.00000 1.00000 1.00000 
Htr1d 1.00000 1.00000 0.99929 1.00000 1.00000 0.00075 0.97581 
Htr1f 0.91148 1.00000 0.00074 1.00000 0.99990 1.00000 0.00245 
Htr3b 1.00000 1.00000 0.03519 1.00000 1.00000 1.00000 1.00000 
Htr7 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Hyal3 0.99996 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ifnk 1.00000 1.00000 0.99981 1.00000 1.00000 1.00000 1.00000 
Ifnl3 0.96795 1.00000 0.00229 1.00000 0.99997 1.00000 0.13360 
Igsf11 1.00000 0.64460 0.99978 1.00000 1.00000 1.00000 0.31266 
Il12rb2 1.00000 1.00000 0.63810 1.00000 1.00000 0.67855 0.00558 
Il24 0.99990 0.60789 1.00000 0.99999 1.00000 0.76901 1.00000 
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Ipp 1.00000 1.00000 0.40140 1.00000 1.00000 0.00010 0.47273 
Iqcj 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Iqgap2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Irf8 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Jam2 1.00000 1.00000 0.33528 1.00000 1.00000 1.00000 0.05637 
Jmjd8 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.99969 
Kcnh3 1.00000 1.00000 0.04012 1.00000 0.74510 1.00000 1.00000 
Klk14 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Krt77 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Krt9 1.00000 1.00000 0.74664 1.00000 1.00000 1.00000 0.01956 
Lcn2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Lima1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Limch1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Lin28b 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.00001 
Lipn 0.99993 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Lman1l 1.00000 1.00000 1.00000 1.00000 1.00000 0.98382 0.99551 
Loxl1 1.00000 1.00000 1.00000 0.99995 0.81536 1.00000 0.80418 
Lpar6 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Lrch1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Lrrc15 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ltbp2 1.00000 0.97685 1.00000 1.00000 0.99999 1.00000 1.00000 
Macrod2 0.94355 0.00004 0.98001 0.96051 1.00000 0.19091 1.00000 
Mag 1.00000 0.46726 1.00000 1.00000 1.00000 1.00000 0.00078 
Mdk 1.00000 0.17186 1.00000 1.00000 0.99983 1.00000 1.00000 
Mdp1 1.00000 1.00000 0.50462 1.00000 1.00000 1.00000 1.00000 
Mepce 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.81046 
Mettl21c 1.00000 1.00000 0.77394 1.00000 1.00000 1.00000 0.04942 
Mettl7b 1.00000 0.91667 1.00000 0.29576 0.10787 0.59416 0.00082 
Mfsd10 1.00000 1.00000 0.99993 1.00000 1.00000 1.00000 0.94635 
Mmp8 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Moxd1 1.00000 1.00000 0.47566 1.00000 1.00000 1.00000 0.99096 
Mpdz 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Mrgpre 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Myh1 1.00000 0.01319 0.91948 0.00007 0.98694 0.00005 
<0.00001
 
Mylip 1.00000 0.00669 0.41814 1.00000 0.03605 1.00000 1.00000 
Myo3b 1.00000 1.00000 1.00000 0.29230 0.07871 1.00000 1.00000 
Myo7b 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.97413 
Nat1 1.00000 1.00000 0.96747 0.99997 1.00000 0.10895 0.99927 
Ncald 0.44568 1.00000 0.00167 1.00000 1.00000 1.00000 0.05868 
Nefh 1.00000 1.00000 1.00000 0.62263 0.04344 1.00000 0.92851 
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Nek11 1.00000 1.00000 0.99636 1.00000 1.00000 1.00000 1.00000 
Nes 1.00000 1.00000 1.00000 0.44716 0.03251 1.00000 
<0.00001
 
Neurl2 0.96514 1.00000 0.00251 1.00000 1.00000 1.00000 0.94709 
Nfatc4 1.00000 0.99960 0.46211 0.23840 1.00000 0.03742 1.00000 
Nmrk2 1.00000 1.00000 0.99911 1.00000 1.00000 1.00000 0.17522 
Npm3 1.00000 1.00000 0.00402 1.00000 1.00000 0.23074 0.46484 
Nrcam 1.00000 0.99856 0.00003 0.64614 1.00000 0.01323 1.00000 
Nrn1l 1.00000 1.00000 0.98253 1.00000 1.00000 0.29187 0.88305 
Nrsn1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Nsun7 0.99945 1.00000 0.99840 1.00000 1.00000 0.91420 0.99999 
Nt5c 1.00000 1.00000 0.99866 1.00000 1.00000 1.00000 1.00000 
Oard1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ocstamp 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.81566 
Ogn 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.94635 
Osm 1.00000 1.00000 0.48178 1.00000 1.00000 1.00000 0.96424 
Pacsin2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Paqr7 1.00000 0.99998 1.00000 1.00000 1.00000 1.00000 1.00000 
Pard6a 1.00000 1.00000 1.00000 0.90411 0.99999 0.91909 1.00000 
Parp16 1.00000 0.97431 0.18518 1.00000 0.72654 1.00000 1.00000 
Parp8 0.28412 0.57899 1.00000 1.00000 1.00000 0.99620 0.99809 
Pcdh12 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Pcsk4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Pitx3 <0.00001 1.00000 <0.00001 <0.00001 1.00000 <0.00001 0.83024 
Pkn3 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Pkp4 1.00000 1.00000 1.00000 0.80459 0.64098 1.00000 0.00003 
Pla2g2d 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Plekha3 1.00000 1.00000 1.00000 0.99998 0.13563 1.00000 1.00000 
Plk5 1.00000 1.00000 0.99997 1.00000 1.00000 1.00000 1.00000 
Pnmt 1.00000 1.00000 1.00000 1.00000 0.99685 0.83489 0.95626 
Postn 0.08822 
<0.00001
 0.96233 1.00000 0.79094 1.00000 0.04203 
Ppp1r26 1.00000 1.0000 0.99999 1.00000 1.00000 1.00000 1.00000 
Ppp1r9b <0.00001 <0.00001 <0.00001 0.00010 <0.00001 0.00019 0.65755 
Prkab1 1.00000 1.00000 1.00000 0.99904 0.52823 1.00000 1.00000 
Prokr1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.38500 
Prom2 1.00000 1.00000 0.35239 0.99999 0.62360 1.00000 1.00000 
Prss40 0.99517 0.99992 1.00000 1.00000 1.00000 1.00000 1.00000 
Prss56 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.99997 
Ptpn20 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ptpn5 0.20353 0.30580 1.00000 1.00000 0.99755 1.00000 1.00000 
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Ptpru 1.00000 1.00000 0.98088 0.59129 1.00000 0.00014 1.00000 
Pycr1 1.00000 0.99758 1.00000 1.00000 1.00000 1.00000 0.86458 
R3hcc1l 1.00000 1.00000 1.00000 1.00000 1.00000 0.99968 1.00000 
Rab11fip5 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Rab20 1.00000 0.99989 1.00000 1.00000 1.00000 1.00000 1.00000 
Rab24 0.60031 1.00000 0.06027 1.00000 1.00000 1.00000 1.00000 
Rab27b 1.00000 1.00000 1.00000 0.17053 0.01980 1.00000 0.87499 
Rab36 1.00000 1.00000 0.87943 1.00000 0.99999 1.00000 0.00022 
Rab39 1.00000 1.00000 1.00000 1.00000 0.99948 1.00000 0.99999 
Rab3ip 0.99674 1.00000 0.03877 1.00000 0.77375 0.81519 0.01999 
Rab43 1.00000 1.00000 1.00000 1.00000 0.99995 1.00000 0.99952 
Rab5a 1.00000 1.00000 0.98602 0.99949 0.99517 1.00000 0.11026 
Rabac1 1.00000 1.00000 1.00000 1.00000 1.00000 0.99996 1.00000 
Rad21l 1.00000 1.00000 0.99001 1.00000 1.00000 1.00000 1.00000 
Rap2b 1.00000 1.00000 1.00000 0.96079 0.95092 1.00000 1.00000 
Resp18 1.00000 0.96304 0.99997 1.00000 1.00000 1.00000 1.00000 
Rexo4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Rhbdl2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.98985 
Rilpl2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Rimklb 1.00000 0.00795 0.00055 1.00000 0.00015 1.00000 0.47273 
Rin3 1.00000 1.00000 1.00000 1.00000 1.00000 0.98209 1.00000 
Rnf10 1.00000 1.00000 1.00000 0.00013 0.00002 0.89154 1.00000 
Rnf112 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Rnf13 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.03397 
Rnf133 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Rnf25 1.00000 1.00000 0.09629 0.22376 0.04616 1.00000 1.00000 
Rps6kl1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Rrad 1.00000 1.00000 1.00000 1.00000 1.00000 0.96571 1.00000 
Rxfp4 1.00000 1.00000 0.25707 0.99998 1.00000 0.87516 0.04697 
Scg2 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Serpina1f 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Serpina7 1.00000 1.00000 0.99997 1.00000 1.00000 1.00000 1.00000 
Serpinb5 1.00000 1.00000 0.00345 1.00000 0.14922 0.18500 0.87780 
Setd6 1.00000 1.00000 0.95386 1.00000 1.00000 0.95874 1.00000 
Sfxn4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Sgta 1.00000 1.00000 0.99372 1.00000 1.00000 1.00000 1.00000 
Sh3tc2 0.88140 1.00000 0.88515 1.00000 1.00000 1.00000 1.00000 
Slc1a1 0.99998 0.07564 1.00000 1.00000 0.25652 1.00000 0.69838 
Slc24a5 1.00000 1.00000 1.00000 0.69724 0.92114 0.99989 1.00000 
Slc25a35 1.00000 1.00000 1.00000 1.00000 1.00000 0.99960 1.00000 
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Slc46a3 0.05127 1.00000 0.00001 1.00000 1.00000 0.60701 0.02093 
Slc8a3 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Slc8b1 0.27322 1.00000 <0.00000 1.00000 0.98869 0.01925 0.00631 
Smoc2 0.99999 1.00000 0.05730 1.00000 1.00000 0.95387 1.00000 
Snx15 1.00000 1.00000 0.12902 1.00000 1.00000 1.00000 0.71906 
Sorbs2 1.00000 1.00000 1.00000 1.00000 1.00000 0.93435 1.00000 
Sox18 1.00000 1.00000 0.99831 1.00000 1.00000 0.14447 0.67412 
Sp5 1.00000 1.00000 1.00000 1.00000 0.98822 1.00000 1.00000 
Spag4 1.00000 1.00000 0.99997 1.00000 1.00000 1.00000 1.00000 
Spp1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Sprr1b 1.00000 1.00000 1.00000 1.00000 0.98382 1.00000 1.00000 
Sprr3 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Sptssb 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Stag3 1.00000 1.00000 1.00000 0.99997 0.37120 1.00000 1.00000 
Stat5b 1.00000 1.00000 0.99969 1.00000 1.00000 1.00000 1.00000 
Stk16 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Stx16 1.00000 0.70597 0.67266 0.57495 0.00105 1.00000 0.00345 
Stx19 1.00000 1.00000 0.99782 1.00000 0.99977 1.00000 0.05429 
Syce1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Syce1l 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Sycp3 1.00000 1.00000 0.99999 1.00000 1.00000 1.00000 1.00000 
Syn3 1.00000 1.00000 0.99413 1.00000 1.00000 1.00000 0.11460 
Tbc1d4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Tbx22 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 0.99999 
Tdrkh 1.00000 1.00000 0.04083 1.00000 1.00000 0.99994 0.00669 
Tex101 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Tex29 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Thsd1 1.00000 1.00000 0.94754 1.00000 0.99941 1.00000 0.20642 
Timp3 1.00000 1.00000 1.00000 1.00000 0.99943 1.00000 1.00000 
Tmem136 1.00000 1.00000 1.00000 0.00254 0.99852 0.00042 1.00000 
Tmem151b 1.00000 1.00000 0.74676 0.61905 0.03149 1.00000 0.99973 
Tmem181 1.00000 1.00000 0.98210 1.00000 1.00000 1.00000 1.00000 
Tmem181a 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Tmem79 0.12915 1.00000 0.00405 0.80889 1.00000 0.03757 1.00000 
Tmod2 1.00000 0.13353 1.00000 1.00000 0.03712 1.00000 0.04314 
Tnfsf18 0.38505 0.99958 0.97423 0.82131 0.94422 0.98041 0.71783 
Tpcn1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Tpgs2 0.03009 0.21296 0.99866 0.37887 0.99354 1.00000 0.95626 
Tppp 1.00000 1.00000 1.00000 0.56355 0.62933 1.00000 
<0.00001
 
Tprn 0.86892 0.80537 1.00000 1.00000 1.00000 1.00000 1.00000 
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Trip13 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Try4 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Tspan18 1.00000 1.00000 1.00000 0.91584 0.96123 1.00000 1.00000 
Tssk5 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ttll10 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Ttll6 0.57716 1.00000 0.00085 1.00000 1.00000 0.08389 0.99824 
Vcpkmt 0.99999 1.00000 0.98888 1.00000 1.00000 1.00000 1.00000 
Vegfb 0.69083 1.00000 0.16113 1.00000 1.00000 1.00000 1.00000 
Vsig4 0.03580 0.00043 1.00000 1.00000 0.06173 1.00000 0.88800 
Vsig8 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Wee2 1.00000 1.00000 1.00000 1.00000 1.00000 0.15328 0.99866 
Ydjc 0.34380 1.00000 0.00005 1.00000 1.00000 1.00000 1.00000 
Ypel1 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Zbtb32 1.00000 1.00000 0.98617 1.00000 1.00000 1.00000 1.00000 
Zbtb4 0.41262 1.00000 0.00975 1.00000 1.00000 0.08996 1.00000 
Zdhhc11 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 1.00000 
Zfp14 1.00000 1.00000 1.00000 0.99996 1.00000 0.70127 1.00000 
Zfp219 1.00000 0.71832 1.00000 1.00000 1.00000 0.99909 1.00000 
Zfp689 1.00000 1.00000 1.00000 1.00000 0.99982 1.00000 0.00579 
Zfp961 1.00000 0.99999 0.00006 1.00000 0.05686 0.00726 0.91956 
Zfyve26 1.00000 0.06976 1.00000 1.00000 0.93841 1.00000 1.0000 
Zzef1 0.99999 0.33032 1.00000 0.96146 0.00138 1.00000 0.15004 
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Chapter 6 Discussion and conclusions  
As much as one-third of human life is spent in sleep, a behavioral state 
characterized by reduced consciousness and increased arousal threshold. Sleep is well 
conserved across mammals and birds, and at least some form of sleep appears common in 
almost all animals.  Sleep is thus believed to serve some important physiological function. 
It has been described as a process “of the brain, by the brain and for the brain” (Hobson 
2005). However, getting sufficient sleep, which is a major health concern, has far-reaching 
health consequences beyond the more obvious deterioration of cognitive performance. 
Insufficient sleep has been implicated in many health conditions including metabolic 
disorders, such as obesity and diabetes, cardiovascular diseases, hypertension, depression, 
and neurodegenerative diseases such as Alzheimer’s disease (AD) (Palagini, Bruno et al. 
2013, Van Someren, Cirelli et al. 2015).  
 
Reports on higher concordance of brain architecture and sleep phenotypes in 
monozygotic vs dizygotic twins provided some of the early evidence that sleep is under 
genetic control (Stassen, Lykken et al. 1988, Ambrosius, Lietzenmaier et al. 2008, De 
Gennaro, Marzano et al. 2008). In 1999, in a major discovery, a mutation in hypocretin 
receptor-2 was found to underlie canine narcolepsy (Lin, Faraco et al. 1999). Many other 
genes since then have been found to affect sleep; in a review, Cirelli summarizes more than 
80 genes that have been reported to alter sleep parameters (Cirelli 2009). There have been 
many advancements in the field of sleep, however, we still lack understanding about the 
fundamental functions of sleep and the need for sleep. This in turn limits our efforts at 
improving sleep quality, and developing more effective drugs for sleep disorders. The 
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knowledge of genetic regulators thus may not only provide an insight into the general 
functions and genetic basis of sleep, but also might suggest novel drug targets to alleviate 
symptoms associated with sleep disorders. To this end, one approach to identify genetic 
components of sleep regulation is by exploiting existing genetic tools and utilizing rodent 
mouse models of human disease conditions. Another possible method to probe the genetic 
basis of sleep is through the use of knockout animals to discover novel sleep-related genes. 
For the first part of my project, I examined an AD mouse model, and a combined mouse 
model of AD and db (diabetes) for alterations in their sleep-wake patterns (Chapters 3 and 
4). For the second part of my thesis, I analyzed data from a large-scale knock out project 
to identify novel sleep-related genes (Chapter 5). 
 
An accurate measure of sleep and sleep-related traits is critical for both forward and 
reverse genetic approaches towards a better understanding of sleep. The different sleep-
wake parameters that can be screened range from sleep duration (REM, NREM sleep), the 
number of such sleep bouts, and distribution of sleep across dark and light phases. To detect 
subtle effects of a gene mutation or an allelic variant in the phenotypic screens, a large 
population of mice is required. However, traditional EEG/EMG techniques used for sleep-
wake assessment has limitations to its scalability for large-scale studies. Not only it is time 
and labor intensive, but also it is an invasive technique which can confound behavioral 
studies, in particular sleep. Furthermore, it requires animals to be tethered to the EEG 
system for data acquisition, which restricts the animal movement. To overcome these 
deficiencies, our lab developed the PiezoSleep system- a high throughput, non-invasive 
system suitable for sleep studies for large numbers of animals. It shows a classification 
accuracy of over 90% compared to human observation and EEG/EMG recordings 
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(Donohue, Medonza et al. 2008, Mang, Nicod et al. 2014). PiezoSleep comprises a highly-
sensitive piezoelectric sensor pad placed on the cage floor. The sensor pad detects the 
pressure variations to classify sleep and wake states. During sleep, the prominent 
movement detected is breathing of an animal compared to wakefulness, which is 
characterized by erratic movements. The system can as well discriminate quiet rest from 
sleep and brief arousals, the feature that is missing in many other non-invasive alternative 
devices. PiezoSleep thus finds its use as an essential tool in all of my research projects. 
However, the system cannot as yet sub-stage sleep into REM and NREM sleep. A detailed 
description of the system can be found in Chapter 2. 
AD, an age-related, progressive neurodegenerative disease, has become a health 
epidemic with more people living beyond their 60s. Sleep alterations are a common 
occurrence, in addition to circadian impairments in many of the AD patients. 
Epidemiological studies indicate that sleep disturbances are one of the primary causes of 
institutionalization of AD patients (Pollak, Perlick et al. 1990, Bianchetti, Scuratti et al. 
1995, Moran, Lynch et al. 2005, Guarnieri, Adorni et al. 2012). Sleep disruptions are 
manifested in the form of reduced slow wave sleep (SWS) andREM sleep, in addition to 
increased nighttime awakenings, and excessive daytime sleepiness (Holth, Patel et al. , 
Prinz, Peskind et al. 1982, Martin, Loewenstein et al. 1986, Vitiello, Prinz et al. 1990, Petit, 
Gagnon et al. 2004). These sleep alterations in turn are believed to be linked to cognitive 
impairments seen in AD patients (Nishida, Pearsall et al. 2009, Walker 2009). Findings 
from human and mouse studies suggest that AD pathology begins as early as 15 years prior 
to the appearance of clinical symptoms, in parallel to sleep aberrations  (Morris and Price 
2001, Sperling, Aisen et al. 2011, Fitzsimmons and Bertram 2013). Improvement in sleep 
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has been found to lower the risk of AD in people with at least one APOE 4 allele (Lim, 
Yu et al. 2013, Simon, Greenaway et al. 2013). Recently, in a seminal work, Xie el al have 
shown that sleep facilitates clearance of toxic metabolites, including A, a neuronal by-
product of the APP protein that is a major constituent of the plaques in Alzheimer’s Disease 
(AD) (Xie, Kang et al. 2013). Taken together, these studies suggest that a bidirectional 
relationship exists between AD and sleep, with poor sleep enhancing the predisposition to 
amyloid beta (A) deposition and reduced clearance, and increasing A causing sleep 
disruption. Thus, sleep may be critical as both a therapeutic intervention for AD, and also 
a key symptom that needs relief.  This information should support further development of 
therapeutics that can alleviate sleep aberrations in AD. Since human studies tend to be 
expensive, take many years, and are difficult to control, animal models are an important 
alternative. Given that a wide variety of genetic resources are well-established for mouse, 
and there is 90% homology between the mouse and human genome in the critical coding 
and gene regulatory regions, the mouse has become a preferred animal model to emulate a 
wide variety of both normal and human pathological conditions, including AD.  
 
In chapter 3, I investigated whether 5XFAD, a well-characterized AD mouse 
model, exhibits sleep-wake alterations similar to those reported in human AD patients. 
These animals show early onset of AD neuropathology as a result of additive effects of 5 
distinct human mutations: 3 in the amyloid precursor protein (APP) namely Swedish, 
Florida and London mutations, and 2 in the presenilin protein (PS1) i.e. M146L and L286V 
(Oakley, Cole et al. 2006). These mice thus develop severe intraneuronal A42  at an early 
age beginning at 1.5 months, amyloid deposition at 2 months, synaptic loss at 9 months of 
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age. Memory deficits as tested on behavioral assays such as Y maze, Morris water maze, 
can be seen at an age of 4 to 6 months onwards (Oakley, Cole et al. 2006). Considering 
that men as well as women are affected by AD, I included both male and female 5XFAD 
mice (4-6.5 months old) in my study. Sleep parameters that were recorded with the Piezo 
system include sleep across 24 h, dark and light phases, and bout length across 24h, dark 
and light phase. After baseline recording of 3-5 days, mice were sleep deprived for 4 hours. 
Under baseline conditions, both male and female 5XFAD mice had shorter bout 
lengths compared to controls. Additionally, females also had reduced overall sleep due to 
marked reduction seen in sleep during the dark phase. However, males did not differ from 
controls in their sleep durations. The bout length reductions for 5XFAD mice (both males 
and females) were more prominent in dark phase (active phase of mice) than the light 
phase, which does not necessarily match the human condition. However, the overall 
decrease still reflects increased sleep fragmentation, which is akin to sleep disruptions seen 
in human AD condition. There was no effect of genotype for bout length and sleep duration 
in 6 h following sleep deprivation (Sethi, Joshi et al. 2015). Thus, in general, our findings 
are similar to previous reports of altered sleep-wake patterns in other AD animals. Reduced 
sleep including REM and NREM sleep, and/ or increased wake time has been reported in 
many AD mice- APP/PS1, PDAPP, TgCRND8, Tg2576 (Huitron-Resendiz, Sanchez-
Alavez et al. 2002, Zhang, Veasey et al. 2005, Platt, Drever et al. 2011, Roh, Huang et al. 
2012, Colby-Milley, Cavanagh et al. 2015). In summary, 5XFAD exhibits sleep alterations 
that resemble some key aspects of sleep disruptions reported in AD patients.  
Sex differences found in our study might stem from difference in A levels for the 
2 sexes. Oakley et al have reported that A42 levels tend to be higher in young 5XFAD 
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females compared to age-matched males (Oakley, Cole et al. 2006). There may be other 
factors contributing to this disparity between the 2 sexes. An understanding of what drives 
these different levels of A in the two sexes may provide further insight to human AD 
sleep alterations as well.   
  Type 2 Diabetes (T2DM), a chronic metabolic disorder, affects more than 8% of 
the American population. Obesity is known to increase the risk for T2DM. In addition, 
inadequate sleep has been linked to elevated risk of T2DM, independently of obesity. It is 
proposed that sleep restriction might alter energy metabolism, by upregulating appetite and 
reducing the energy expenditure (Knutson, Spiegel et al. 2007). These events in turn can 
lead to weight gain, and contribute to insulin resistance, which again is a risk factor for 
developing T2DM. Animal studies further corroborate the inverse relationship between 
sleep and metabolism. Leptin-deficient ob/ob, and leptin-resistant db/db mice and obese 
zucker rats have attenuated sleep-wake rhythms in addition to increased sleep 
fragmentation, and increased overall sleep duration (Mavanji, Billington et al. 2012). 
Conversely, type, timings and availability of diet, has been shown to affect sleep in rodents  
(Jenkins, Omori et al. 2006).  
 
Furthermore, there is growing evidence that diabetes and obesity present an 
increased risk of AD development. The Rotterdam study, and several more recent studies, 
have shown that diabetic individuals have double the risk of AD prevalence (Ott, Stolk et 
al. 1999, Kroner 2009). In a clinical study, Janson et al found that AD patients are more 
prone to develop T2DM than non-Alzheimer controls (Janson, Laedtke et al. 2004). The 
individuals with AD, and a prior history of T2DM also exhibit cerebrovascular 
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abnormalities, in addition to the typical AD-related neuropathology without showing any 
additional A burden. Effects of cerebrovascular anomalies or vascular dementia, a 
frequent comorbidity with Alzheimer’s disease, are poorly understood. An animal model 
recapitulating- both AD and T2DM, is therefore critical to further our understanding about 
how the two conditions interact, and promote cerebrovascular abnormalities. 
 With the aim to evaluate how the interaction of AD and T2DM affect sleep, I took 
advantage of the combined mouse model of AD and T2DM (db/AD) created by Niedowicz 
et al. The db/AD mouse was generated by crossing leptin-resistant db/db with APP/PS1, a 
knock-in mouse model of AD (Neidowicz et al., 2014). db/AD mice exhibit additional 
cerebrovascular pathologies (aneurysms and strokes), not present in either of the parental 
lines. These animals are obese, insulin resistant and glucose tolerant beginning early age. 
Plaque deposition is reduced in db/AD animals compared to AD mice. A levels do not 
differ between db/AD animals relative to AD mice across different age groups. However, 
A42 levels are reduced significantly in db/AD animals than AD mice, at 6 and 12 months 
of age (Neidowicz et al., 2014). 
For my study, as detailed in chapter 4, I assessed sleep duration and bout length in 
db/AD mouse, as well as individual parental strains- db/db and APP/PS1, for comparisons. 
We included mice of both the sexes and different age groups (young and old), and 
examined the interaction effects between different predictor variables. Our findings are 
similar to previous reports on AD animals. In our study, AD animals slept less during dark 
phase, and also had longer bout lengths during the light phase and across 24h, after 
controlling for all other covariates. It is thus possible that AD animals tend to compensate 
for shorter sleep duration seen during dark phase, with longer sleep bouts during the light 
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phase (an increase in average bout lengths by approx. 100 s). db animals were found to 
have longer overall duration of sleep, attributable to prominent differences seen during the 
dark phase. This is similar to previous reports in case of leptin-deficient ob/ob and leptin-
resistant db/db mice, and Obese zucker rats.  
For db/AD mice (both males and females) similar to db animals, an increase in 
sleep duration across 24 h and dark phase compared to controls was found. Our findings 
thus indicate that the cerebrovascular pathology seen in db/AD mice, believed to be 
responsible for their cognitive deficits does not lead to additional sleep aberrations. Also, 
Niedowicz et al in their studies reported that db/AD animals have less plaque deposition 
and A42 levels than AD animals (Neidowicz et al., 2014). This might explain a more 
prominent effect of db genotype on sleep measures than AD in case of db/AD mice.  
We found significant age and db/AD genotype interactions for sleep across 24h, 
light as well as dark phase, which means that as db/AD mice grow older; they tend to sleep 
less. Reduction in sleep duration tends to be more salient during the dark phase. These 
findings indicate that with an increase in age for db/AD animals, they sleep less than when 
they are young, and thus the sleep differences dissipate between db/AD and WT animals 
at later age. 
Sex effects were seen in case of bout lengths, as females tend to have shorter bouts 
compared to males and these differences were more prominent in dark than the light phase. 
In regard to age difference, older subjects were found to have shorter bouts during the light 
phase. Interaction between sex and age was found to be significant for the older animals 
for bout length during the dark phase implying that there is reduction in bout length as the 
age progresses for any of the given genotype. 
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Leptin can be one of the upstream molecular components involved at the 
intersection of AD and diabetes. It is known to activate MAPK, AKT and mTOR kinases, 
which are known to inhibit Glycogen synthase 3 kinase (GSK3B) and thus GSK3B-
dependent tau phosphorylation. Down-regulation of leptin signaling as seen in T2DM can 
therefore result in increased tau phosphorylation which can subsequently promote AD 
development (Shiromani, Xu et al. 2004, Bertram, Rook et al. 2011). Collectively, these 
studies suggest that diabetes associated dysfunctions promote AD pathology which can 
then disrupt sleep. Conversely, sleep impairments might be augmenting the AD and T2DM 
diseased states. Further interrogation of the underlying pathways can bridge the gap in our 
understanding of how sleep, AD and diabetes are inter-connected. In particular, it will be 
interesting to trace the molecular mechanisms that lead to reduced plaque deposition and 
A42 levels in db/AD animals, which might be significant in developing novel drug targets 
aimed at ameliorating AD pathology.  
There are many mechanisms to determine genetic regulators of sleep. Each of the 
available techniques has its own strengths and limitations, and together have advanced our 
understanding about sleep. For my research, I mainly took advantage of reverse genetics 
techniques. In my earlier chapters, I utilized a variety of mouse models recapitulating 
human diseased conditions and assessed if they are similar in their sleep-wake phenotype 
to human conditions.  For my fifth chapter, I report identification of novel sleep-related 
genes by screening sleep-wake parameters for a large-scale population of single gene 
knockout mice being recorded as part of Knockout mouse phenotyping program (KOMP2) 
(Abbott 2010, Bradley, Anastassiadis et al. 2012, Brown and Moore 2012). Sleep-wake 
traits were analyzed by PiezoSleep system. Knockout mice were generated on C57BL6/N 
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background, a common laboratory inbred strain. The mice are being recorded at the 
Jackson Laboratory (Jax), one of the KOMP2 centers. As part of the Jax phenotyping 
pipeline, each of the mouse is comprehensively screened for over 200 measurements, 
ranging from morphological, physiological to behavioral traits. Additional behavioral 
assays such as rotarod, holeboard exploration tests, and sleep, are unique to Jax pipeline.  
  These knockout mice were recorded for 5 baseline days, under 12:12 LD conditions 
at the age of 15 weeks. To date, I have analyzed data for more than 6000 animals, 
representing over 300 knockout lines, and over 1800 control animals. I have identified 55 
novel sleep-related genes by utilizing multiple statistical approaches including ANOVA, 
Principal component analysis and Multivariate analysis (Mahalanobis distance). 
Significant sleep-wake differences were found for a number of knockout strains relative to 
controls, in both light and dark phase. Some of the shortlisted candidate sleep genes are 
Adck2, Bzw2, Cbln3, Cpb1, Htr1d, Pitx3, Ppp1r9b, Rab27b, Rab36, Rimklb, Rnf10 and 
Tmem136. For many of the genes not much is known as is the case for Tmem136 and 
Rimklb while others have been associated with a wide variety of functions such as neuronal 
differentiation, modulating dendritic morphology, protein-protein interactions, and signal 
transduction. But none of these genes have been implicated in sleep regulation before, other 
than Htr1d and Pitx3.  
Additionally, sex differences were found for controls and many of the knockouts. 
Females slept less than males in most of these cases. Amongst other behavioral assays in 
the pipeline, sleep has been found to be the most consistent, which is not surprising given 
that sleep is a tightly regulated process and plays a critical role in overall health of an 
126 
 
animal. In addition to sleep traits, we also recorded breath rate for the knockout and control 
animals and found several genes affecting breathing variables as well. 
This project demonstrates the potential of an unbiased approach such as KOMP2 
in underscoring the role of novel genes, not implicated in sleep regulation earlier. The 
wealth of data generated by KOMP2 is unprecedented in sleep research. This analysis may 
not be the final step in functional annotation of sleep-related genes, but one crucial step 
towards our understanding of sleep regulation. Further follow up from our lab and other 
researchers would hopefully yield success in our quest to answer the questions of why do 
we need sleep and how are the genes implicated from these genetic studies responsible for 
its regulation and functions. 
 For the follow up, next logical extension of this project will be to elucidate the 
mechanisms through which our novel, candidate sleep genes regulate sleep. In particular, 
knockouts for the genes- Ap4e1, Ppp1r9b and Cbln3, which affect multiple sleep-wake 
traits can be followed primarily for the gene expression studies. Based on their RNA seq 
analysis results, consistently upregulated or downregulated genes (especially in brain) 
common to all the knockouts, can be studied further. Pathways of genes shortlisted based 
on their common occurrence can then be investigated, and knockout mice be generated for 
the gene/s thought to be upstream or downstream of the pathway of the deleted gene. 
Generation of knockouts is a time consuming process; an alternative could include the use 
of morpholinos, targeting the gene. Rescue experiments may be conducted for the 
suggested target downstream gene/s by introduction of its wild type transgenes in the 
knockout mouse. Pharmacological agonists/ antagonists could also be tried if appropriate. 
Complete/ partial rescue of the phenotypes and restoration of expression levels of the 
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affected genes, similar to the control, would implicate the gene as a downstream target and 
would lead us to hypothesize the pathway by which aforesaid genes might play a role in 
sleep regulation. Other assays/ approaches will be helpful in framing the hypothesis. In-
situ hybridization (ISH) can locate the site of expression of the affected gene/s in the brain. 
Expression in some specific region of the brain might correlate with the observed 
phenotypes or might give further clues to the other possible functions of the gene. An 
alternative to ISH will be the use of public databases (such as Allen’s Brain Atlas or 
BioGPS). Behavioral assays (such as learning and cognitive tasks) could be performed for 
the KO mice before and after transgene introduction to find if the behavioral phenotypes 
(if there were any), could be rescued too.  
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